Somatostatin receptor scintigraphy in malignant lymphoma by Lugtenburg, P.J. (Pieternella)
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
IN MALIGNANT LYMPHOMA 
The support of this thesis by Mallinckrodt Medical BV, Roche, Janssen-Cilag, 
Amgen, Wyeth and Pfizer is gratefully acknowledged. 
© P.J. Lugtenburg, Rotterdam, the Netherlands, 2001 
ISBN 90-7701720-8 
Printed by Optima Grafische Communicatie, Rotterdam 
Somatostatin Receptor Scintigraphy 
in Malignant Lymphoma 
Somatostatine receptor scintigrafie 
in maligne lymfomen 
Proefschrift 
ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificos Prof.dr.ir. J.H. van Bemmel 
en volgens besluit van bet College voor Promoties 
De openbare verdediging zal plaatsvinden op 
woensdag 28 november 2001 om 13.45 uur 
door 
Pieternella Johanna Lugtenburg 
geboren te Rotterdam 
Promotiecommissie 
Promotoren: 
Overige !eden: 
Prof.dr. B. Lowenberg 
Prof.dr. E.P. Krenning 
Prof.dr. A. Hagenbeek 
Prof.dr. P.C. Huijgens 
Prof.dr. S.W.J. Lamberts 
'We don 't see things as they are, we see them as we are'. 
(Anais Nin) 
Voor Ineke en Deborah 
CONTENTS 
Abbreviations 9 
Chapter I Introduction 
1.1 
1.2 
1.3 
1.4 
1.5 
1.6 
1.7 
1.8 
Chapter 2 
Chapter 3 
Chapter 4 
Chapter 5 
Malignant lymphomas 
Staging of Hodgkin's disease and non-Hodgkin's 
lymphoma 
Conventional imaging techniques 
Gallium scintigraphy 
FDG-PET scintigraphy 
Somatostatin and somatostatin receptor scintigraphy 
Aim of the study 
References 
Somatostatin receptor scintigraphy in the initial staging 
of Hodgkin's disease 
BrJ Haemato/93: 96-103. 1996 
Somatostatin receptor scintigraphy in cutaneous malignant 
lymphomas 
JAm Acad Dermato/34: 985-993. 1996 
Somatostatin receptor scintigraphy useful in stage I-II 
Hodgkin "s disease: more extended disease identified 
Br J Haemato/112: 936-944. 2001 
Somatostatin receptor scintigraphy in the initial staging 
oflow-grade non-Hodgkin"s lymphomas 
J Nucl Med 42: 222-229, 2001 
13 
17 
19 
20 
22 
23 
27 
28 
39 
57 
73 
93 
Chapter 6 
Chapter 7 
7.1 
7.2 
7.3 
7.4 
7.5 
7.6 
Samenvatting 
Somatostatin receptor scintigraphy in the initial staging 
of intermediate- and high-grade non-Hodgkin"s lymphomas 
Haematol J in press 
Summary and general discussion 
Place ofSS-R scintigraphy in the staging of Hodgkin"s disease 
Place ofSS-R scintigraphy in the staging ofnon-Hodgkin's 
lymphoma 
Future issues in imaging Hodgkin's disease and 
non-Hodgkin"s lymphoma 
New developments in SS-R imaging 
SS-R imaging as a guide in targeted treatment 
References 
List of publications 
Dankwoord 
Curriculum Vitae 
113 
137 
138 
139 
141 
143 
144 
149 
152 
154 
156 

Abbreviations 
Bq 
CBCL 
CT 
CTCL 
DTPA 
FDG 
Ga 
GH 
HD 
hSSTR 
mCi 
MRI 
NHL 
PET 
SPECT 
ss 
SS-R 
TSH 
Becquerel 
Cutaoeous B'celllymphoma 
Computed tomography 
Cutaneous T -cell lymphoma 
Diethylenetriaminopentaacetic acid 
2-[18F]-fluoro-2-deoxy-D-glucose 
Gallium 
Growth hormone 
Hodgkin's disease 
Human somatostatin receptor 
Millicuries 
Magnetic resonance imaging 
Non-Hodgkin 's lymphoma 
Positron emission tomography 
Single photon emission computed tomography 
Somatostatin 
Somatostatin receptor 
Thyroid stimulating hormone 
9 

CHAPTER I 
Introduction 

INTROD\JCTION 
The prognosis of patients with malignant lymphomas has improved over the last 30 years. 
Besides from improvements in therapy the better outcome of these patients has resulted 
also from the introduction of better diagnostic techniques detecting involved sites. 
Diagnostic radiology plays an essential role in assessing the extent of disease. Imaging 
studies are also important in assessing the response to treatment, evaluating complications 
of treatment and demonstrating relapse of disease. Imaging techniques that are frequently 
used include: conventional frontal and lateral chest radiographs, computed tomography 
(CT) scanning, ultrasound and magnetic resonance imaging (MRI). The choice of the 
techniques preferably used is based on patterns of dissentination of the disease and the 
diagnostic accuracy of the test in terms of sensitivity and specificity. However, factors 
such as patient acceptance, availability of expertise and equipment and cost may also play 
a role. Accurate staging and re-staging is critical to the selection of treatment in the 
interest of improved outcomes. 
1.1 Malignant lymphomas 
Currently, about 2500 new cases of malignant lymphomas per annum occur in the 
Netherlands. Approximately 80% of cases are non-Hodgkin's lymphomas (NHL) and the 
other cases are Hodgkin's disease (HD) (!).There are considerable differences between 
HD and NHL as regards pathogenesis, pathobiology, clinical presentation, response to 
therapy and prognosis. 
In econontically advantaged populations the incidence of HD peaks in the third decade of 
life and at 65-75 years. The diagnosis is usually made following the pathological 
examination of an excised lymph node. The diagnosis of classical HD is established 
through the identification of Hodgkin's cells, either by histopathology or histopathology 
combined with immunohistochemical studies, in the appropriate cellular milieu. 
According to the World Health Organization classification classical HD can be 
subdivided in four histologic subtypes (2) (Table l ). 
Table I. WHO classification ofHod~kin's lymphoma (Hodgkin's disease) 
Nodular lymphocyte-predominant Hodgkin's lymphoma 
Classical Hodgkin's lymphoma 
Nodular sclerosis Hodgkin ·s lymphoma 
Lymphocyte-rich classical Hodgkin's lymphoma 
:.1ixed cellularity Hodgkin's lymphoma 
Lymphocyte depletion Hodgkin's lymphoma 
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The nodular sclerosis subtype is most common, accounting for more than two-thirds of all 
cases in Western populations. The mixed cellularity subtype comprises approximately 
30% of cases. The lymphocyte-rich and lymphocyte depletion subtypes are seen 
relatively infrequently. In addition, nodular lymphocyte-predominant HD has distinct 
biologic. histologic and clinical features. Most patients present with localized peripheral 
disease often in the neck (3). The majority of patients with the nodular sclerosis subtype 
of HD present with disease above the diaphragm and mediastinal involvement (3 ). HD 
appears to begin at a certain localized lymphoid site and clinically progresses to involve 
adjacent lymphoid tissues before disseminating to distant nonadjacent sites and organs. 
Noncontiguous spread and hematologic distribution are more common with recurrent 
disease (4). As the prognosis ofHD gets worse at more progressive stages of the disease, 
treatment of HD is largely determined by disease extent. Patients with limited disease 
(stages I and II) may be effectively treated with regional radiotherapy alone. However, in 
30% of cases the disease may recur (5). These patients usually relapse in previously 
unirradiated sites (6,7). Therefore, nowadays in patients with limited disease prognostic 
factors are used to identify patients at higher risk for relapse and these are no longer 
treated with local (radio)therapy alone (6,8). Patients with advanced disease (stages III 
and IV) are treated with systemic chemotherapy (9). The majority (50-90%) of patients 
with HD become long term disease free survivors (9,10). 
The incidence of NHL increases from the fifth. decade of age onwards. The diagnosis is 
made following the histopathologic. immunologic and sometimes molecular examination 
of a tissue biopsy. Several pathological classification systems have been proposed for the 
classification ofNHL. In Europe during the last decennium the ''Kiel-classification" has 
been used by most pathologists and in the USA the "Working Formulation" (11,12). The 
Working Formulation defines three prognostic groups that are designated as: low-grade, 
intermediate-grade and high-grade histologies (Table 2). In 1994 the "Revised European-
American Lymphoma (REAL) classification for lymphoid neoplasms has been proposed 
(13). In the REAL classification molecular and cytogenetic features are taken into 
account in addition to histopathologic and immunohistochemic information. The REAL 
classification makes a clear distinction between histological or cytological grade and 
clinical aggressiveness. Histological grade is based on cell and nuclear size, density of 
nuclear chromatin and the proliferation fraction as assessed by the number of mitotic 
figures or the proliferation fraction determined by Ki-67 staining. By and large, 
histological grade correlates with clinical aggressiveness but this is not always the case. 
Mantle cell lymphoma is histologically low grade but clinically aggressive, as are some 
T -cell lymphomas as angioimmunoblastic T -cell lymphoma. 
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Table 2. The .Kational Cancer Institute Working Formulation 
Low grade 
A Malignant lymphoma, small lymphocytic 
consistent with CLL 
plasmacytoid 
B Malignant lymphoma, follicular. Predominantly small cleaved cell 
diffuse areas 
sclerosis 
C ::0alignant lymphoma, follicular. Mixed, small cleaved and large cell 
diffuse areas 
sclerosis 
Intermediate grade 
D Malignant lymphoma, follicular. Predominantly large cell 
diffuse areas 
sclerosis 
E Malignant lymphoma, diffuse. Small cleaved cell 
sclerosis 
F Malignant lymphoma, diffuse. Mixed small and large cell 
epithelioid cell component 
sclerosis 
G Malignant lymphoma, diffuse. Large cell 
cleaved cell 
non-cleaved cell 
sclerosis 
High grade 
H Malignant lymphoma. Large cell immunoblastic 
plasmacytoid 
clear cell 
polymorphous 
epithelioid cell component 
Malignant lymphoma. Lymphoblastic 
convoluted cell 
non-convoluted cell 
J Malignant lymphoma. Small non-cleaved cell 
Burkitt's 
follicular areas 
Miscellaneous 
Composite 
:viycosis fungoides 
Histiocytic 
Extramedullary plasmacytoma 
Unclassifiable 
Other 
INTRODGCTION 
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Both the Working Formulation and Kiel-classification stressed the fundamental 
importance of 'grade', although using the term in a different sense, in determining 
treatment. The REAL classification instead lays stress on the disease entity (13,14). In 
Table 3 distinct lymphoma entities are listed according to their clinical aggressiveness. 
Table 3. Lymphoma entities according to the REAL classification categorized according to 
clinical behavior 
Highly aggressive 
Lymphoblastic lymphoma 
Burkitt's lymphoma 
Aggressive 
Diffuse large B-celllymphoma 
Angioimmunoblastic T -cell lymphoma 
Anaplastic large cell (CD 30+) lymphoma 
(Mantle cell lymphoma) 
Indolent 
Small lymphocytic lymphoma 
L ymphoplasmacytoid lymphoma!immunocytoma 
Follicle center lymphoma, follicular 
Marginal zone B-celllymphoma, incl. :MALT lymphoma 
Mycosis fungoides 
However, it is important to realize that many of these lymphoma entities have a range of 
morphologic grade and clinical aggressiveness. Examples are the follicle center 
lymphomas, but also the mucosa-associated lymphoid tissue (MALT)-type lymphomas, 
angiocentric lymphomas and even mantle cell lymphomas can apparently have relatively 
lower and higher grade types (13). The course of NHL is less dependent on disease 
extent, but more on the histological subtype and grade of malignancy. The large majority 
of patients with indolent or low-grade NHL have disseminated disease at diagnosis. Bone 
marrow involvement is characteristic. In general the disease presents as a slowly 
progressive disorder. The median survival has been estimated at about 8 years (15). When 
determining a therapeutic plan, it is first important to identify those patients with 
localized disease (stages I and II) potentially eligible for regional irradiation. Long-term 
disease-free survival may be achieved in approximately half of such patients following 
radiotherapy (16, 17). Therefore, in case of staging patients with indolent NHL it is 
important to identify the small proportion of patients with truly localized disease. The 
aggressive NHL respond well to chemotherapy, however the more advanced stages have 
a high tendency for recurrence. In patients with aggressive NHL it appears useful to 
distinguish between stages I and stages II-IV disease. The majority of patients (80-90%) 
16 
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with clinical stage I disease can be treated effectively with short-course combination 
chemotherapy with or without radiotherapy (18-20). The treatment of choice for patients 
with more advanced disease is combination chemotherapy and overall approximately 
30% of adults up to the age of 60 years will survive free of disease at the long term 
(21,22). 
1.2 Staging of Hodgkin's disease and non-Hodgkin's lymphoma 
Once the diagnosis of malignant lymphoma has been established the extent of the disease 
has to be determined and clinical staging is undertaken. Since 1971 the Ann Arbor 
staging classification has been applied (23 ). It was formulated to provide a system. which 
would allow for decisions on treatment choice in patients at initial presentation. The 
specifications of the Ann Arbor classification are given in Table 4. 
Table 4. The Ann Arbor staging classification 
Stage I 
Stage II 
Stage III 
Stage IV 
Symptoms 
Involvement of a single lymph node region (I) or single extralymphatic organ or 
site (I,) 
Involvement of 2 or more lymph node regions on the same side of the diaphragm 
(II) or localized involvement of extralymphatic organ or site and of 1 or more 
lymph node regions on the same side of the diaphragm (liE) 
Involvement oflymph node regions on both sides of the diaphragm (III). which 
may also be accompanied by localized involvement of extralymphatic organ or 
site (IIIE) or by involvement of the spleen {Ills). or both (IIIsE) 
Diffuse or disseminated involvement of 1 or more extralymphatic organs or 
tissues with or without associated lymph node involvement 
A 
B 
Asymptomatic 
Unexplained fever with temperatures above 38°C 
Night sweats 
Unexplained weight loss of more than 10% of body weight in the 
previous 6 months 
The classification was originally introduced for the staging of HD and was based on the 
concept that HD initially spreads in a predictable fashion towards contiguous lymph node 
chains. In the following tvventy years new features of prognostic importance have been 
recognized, e.g. "'bulk" of mediastinal involvement, number of nodal areas involved and 
other clinical features, i.e. age, sex, B-symptoms and erythrocyte sedimentation rate 
(6,24-27). Subsequently, new imaging techniques like CT scanning and MRI became 
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available and were introduced into routine staging. In 1988 a meeting was organized in 
the Cotswolds. England. to update the Ann Arbor classification and account for the use of 
imaging techniques such as CT scanning (28). Details of the Cotswold meeting 
recommendations for clinical imaging criteria are given in Table 5. 
Table 5. The Cotswold meetin~ recommendations for clinical imaging criteria 
CT scan Lymph nodes of more than 1.5 em cross-sectional diameter are unequivocally 
abnormal on CT scanning 
Spleen Involvement requires unequivocal palpable splenomegaly alone. or equivocal 
palpable splenomegaly with radiological confirmation of either enlargement or 
multiple focal defects which are neither cystic nor vascular 
Liver Multiple focal defects which are neither cystic nor vascular noted with at least two 
imaging techniques 
Lung Radiological evidence of parenchymal involvement in the absence of other likely 
causes especially infection 
Bulk A node or nodal mass must be 10 em or greater to be recorded as 'bulky' 
Whereas in HD the prognosis is distinctly worse with each progressive stage of disease~ 
and treatment approach depends on disease extent, this is not as clearly true in NHL. 
Prognosis of NHL depends on the histopathologic subtype and certain clinical 
parameters~ rather than stage of dissemination. Thus, the Ann Arbor classification is 
clinically less useful in patients with NHL. In NHL various prognostic factors have been 
applied. The International Non-Hodgkin"s Lymphomas Prognostic Factors Project (1993) 
reported a predictive model for aggressive NHL (29). On the basis of age, stage, serum 
lactate dehydrogenase (LDH) levels. performance status and number of extranodal 
disease sites, four distinct risk groups have been identified with variable predicted five-
year survival rates. The international prognostic index and age-adjusted international 
prognostic index are significantly more accurate in predicting long-term survival than the 
Ann Arbor classification (29). In low-grade lymphomas the international prognostic 
index also expresses prognostic value (30,31 ). Despite the shortcomings of the Ann Arbor 
classification, it is a convenient method for defining and reporting the disease extent and 
thus the Ann Arbor classification remains the most commonly used staging system for 
both HD and NHL. 
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1.3 Conventional imaging techniques 
For the initial clinical staging of malignant lymphomas a detailed history, complete 
physical examination, bone marrow aspiration and/or biopsy and several imaging studies 
are generally recommended (28.32). Nowadays, most centers perform chest radiographs 
and CT scans of the thorax. abdomen and pelvis, using intravenous contrast whenever 
necessary and with images at 1.0 em intervals. Sometimes additional imaging techniques 
are applied as well. These may include ultrasound scanning of the neck and/or abdomen 
and MRI. In case of specific symptoms or physical signs special investigations and 
imaging studies may be performed to confirm clinical involvement at a given site e.g., 
radionuclide bone scanning, barium studies and endoscopies. 
The most common clinical presentation of malignant lymphomas is an asymptomatic 
enlarged lymph node, often located in the neck. Studies reporting on diagnosis of 
peripheral lymphadenopathy in patients with malignant lymphoma have been scarce. Two 
studies showed that in 10-18% of lymphoma cases more pathologic lymph nodes were 
detected with ultrasound scanning, following physical examination (33)4). Imaging of 
the neck with ultrasound or CT scanning is increasingly being employed. 
Intrathoracic disease at presentation is more often seen in patients with HD than in NHL. 
Frontal posteroanterior and lateral chest radiographs are generally done in patients with 
newly diagnosed malignant lymphoma. Various studies have shown that CT scans of the 
thorax clearly reveals disease at sites that, even in retrospect, are not revealed on 
conventional chest radiographs (35-37). Importantly, based on the added information 
provided by the CT scans treatment choice was modified in up to 60% of patients (36_37). 
Lymph node sites that are readily demonstrated on CT scans and difficult to evaluate on 
chest radiography, include the subcarinaL cardiophrenic angle and internal mammary 
lymph node groups. In addition, CT scans have a greater accuracy in detecting lung 
parenchymal abnormalities, pericardia! involvement and chest wall involvement. CT 
scanning currently represents the standard for chest imaging in patients with malignant 
lymphoma. MRI may be useful in specific situations, such as assessment of chest wall 
invasion (38). 
Based on laparotomy evaluations, approximately 35% of patients with HD have 
subdiaphragmatic involvement (39). Abdominal disease is more frequent in NHL. Prior 
to the introduction of CT scanning, lymphangiography has been the method of choice to 
determine the presence of subdiaphragmatic disease. Abnormal distortion of the lymph 
node architecture due to replacement provides a positive sign of tumor involvement and 
this feature is an advantage of lymphangiography. Based on direct comparisons with 
staging laparotomy data, lymphangiography shows a slightly improved sensitivity and 
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specificity as compared to CT when evaluating retroperitoneal lymph nodes ( 40-42). 
Nevertheless, lymphangiography is no longer commonly employed, as CT scanning is 
considerably easier to perform and less labor intensive. CT diagnosis of 
lymphadenopathy is based on detection of lymph nodes > 1.0 em in short-axis 
measurements. Other imaging techniques. such as ultrasound and MRI similarly rely on 
lymph node size criteria. Data on the accuracy of CT for evaluating subdiaphragmatic 
lymph nodes and organ involvement are limited (40,42,43). Published results have been 
obtained with CT scanners that were used in the late 1970s and early 1980s. Updated 
analyses of the value of the more advanced CT scanners that provide higher spatial 
resolution are not yet available. CT scanning has been estimated to perform at low 
sensitivity for detecting positive lymph nodes in the upper abdomen (38%-80%), spleen 
(15%-33%) and liver (19%-25%) (Table 6) (40,42,43). 
Table 6. Abdominal CT scanning in Hodgkin's disease 
Gold standard: histologic dia~nosis based on laparotomy 
First-named Ref. Patient no. Sensitivity 
author para-aortic nodes 
% 
Jonsson (43) 42 so 
Castell ina (40) 121 65 
Mansfield (42) 87 38 
Sensitivity 
spleen 
% 
31 
33 
15 
Organ size appears a poor criterion for liver and spleen involvement, unless the 
enlargements ofliver or spleen are marked. CT, MRl and ultrasound can also reveal focal 
deposits of lymphoma that are 1.0 em in size or larger. However, in most instances, 
dissemination to the liver and spleen results in one or more subcentimeter deposits of 
lymphoma that are difficult if not impossible to detect with current cross-sectional 
imaging techniques. 
1.4 Gallium scintigraphy 
In 1969 Edwards and Hayes were the first to report gallium (67Ga) uptake in patients with 
HD (44). The mechanism of this tumor uptake is incompletely understood, however it 
reflects metabolic activity and tumor viability (45,46). Gallium scintigraphy is not 
generally used in staging and restaging of HD and NHL. This is in part due to the 
variability of techniques used for gallium imaging. The usefulness of gallium studies 
depends on optimal equipment and technique (47). The recommended dose of 67Ga in 
adults is at least 8 to 10 mCi. Single-photon emission computed tomographic (SPECT) 
imaging of thorax and abdomen and delayed studies are essential ( 48,49). This makes the 
procedure expensive and time consuming. Literature data regarding the use of gallium 
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scanning for the initial staging of patients with malignant lymphomas, using high dose 
67Ga, SPECT imaging and modem equipment are scarce (Table 7) (48-54). 
Table 7. Gallium scintigraphy studies in the initial staging of malignant lymphoma 
First-named Study Patient Patient Sensitivity Sensitivity Sensitivity Sensitivity 
author no. group above below per site per 
(ref) diaphragm diaphragm overall patient 
% % % % 
Tumch R 40 HD 96 85 NA NA 
(48) KHL 
Front R 77 HD 88 79 85 NA 
(49) NHL 
Hagemeister R 41 HD 64 31 51 NA 
(50) 
Larcos R 46 HD NA KA 67 NA 
(51) :-lHL 
Waxman p 36 HD NA ~A 61 89 
(52) NHL 
Ben-Haim R 40 LG- 68 72 69 so 
(53) NHL 
Gallamini R 48 LG- KA NA 41 50 
(54) NHL 
R. retrospective: P. prospective: HD. Hodgkin's disease: NHL. non-Hodgkin 's lymphoma; LG-NHL. low-
grade non-Hodgkin 's lymphoma; NA. not applicable. 
Most studies are retrospective and the numbers of patients in those studies have been 
small. As regards the evaluation of abdominal lymph nodes and viscera, a low sensitivity 
ranging from 31%-85% has been reported for gallium scintigraphy ( 48-50). The 
visualisation of abdominal pathology is hampered by the high uptake of the radionuclide 
in the liver, spleen and intestines. For supradiaphragmatic sites the sensitivity and 
specificity of gallium imaging may range from 64%-96% (48-50,53). The overall 
sensitivity of CT scanning is better than that of gallium scintigraphy (49,52-55). 
Therefore, the use of gallium scintigraphy as an initial staging procedure has not become 
established general practice. 
Masses that remain after treatment for lymphoma constitute a common and difficult 
diagnostic problem. With careful restaging by chest radiography and CT, many patients 
have residual masses after therapy (56-58). In many cases such residual masses .consist of 
residual fibrotic tissue with no active lymphoma, whereas in other cases active residual 
disease may still be present. Recently, some reports have stressed the potential usefulness 
of SPECT gallium scanning to discriminate between active residual tumor and benign 
fibrous tissue. Several studies using SPECT gallium scans after therapy for aggressive 
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NHL have demonstrated some effectiveness in the use of this technique (57,59,60). In 
one study the predictive value of a positive posttreatment gallium scan was significantly 
higher (73%) than that of a positive CT (35%) (59). In another study the predictive value 
of CT and SPECT gallium scanning in the disease-free survival of patients receiving 
high-dose chemotherapy and autologous stem-cell transplantation for NHL was evaluated 
( 60). In patients with diffuse aggressive NHL SPECT gallium scanning was highly 
predictive of eventual outcome and was more predictive than the CT scan results. 
However, for patients with follicular NHL the addition of SPECT gallium scanning to CT 
scanning did not add substantially to the evaluation of transplant outcome ( 60). Gallium 
imaging is less efficacious in intra-abdominal tumors and indolent NHL. Thus its value in 
monitoring the response to therapy and in follow-up in these cases is limited (53,54). The 
role of posttreatment gallium scans in the routine management of Hodgkin's disease 
remains unclear. The technique is particularly useful for evaluating mediastinal sites, but 
less for the evaluation of the abdomen. A positive gallium scan after therapy, although 
unusual in patients with Hodgkin's disease, should be considered a manifestation of gross 
residual disease and resistance to treatment (55,58,61-64). A negative posttreatment scan, 
although clearly more favorable than a positive scan, was reported not highly predictive 
of cure in patients with stage III to IV disease (63,64). These results suggest that the 
apparent excellent predictive value of a negative posttreatment study that has been 
reported in series of mostly stage I to II patients may be due to the fact that so few 
patients with early-stage disease relapse (59,62). 
LS FDG-PET scintigraphy 
Positron emission tomography (PET) is a form of computed tomography that produces 
images of biochemical and physiological processes in tissue. Tumors are visualized as 
areas of increased uptake of the tracer. PET with 2-[18F]-fluoro-2-deoxy-D-glucose 
(FDG) produces images of regional tissue glycolytic activity. Malignant tissues exhibit 
increased rates of glycolysis. Whole-body FDG-PET generates tomographic images of 
the entire patient and show the distribution ofFDG throughout the body. 
FDG imaging in lymphoma was first reported in 1987 by Paul, who demonstrated high 
FDG uptake in 4 NHL patients (65). The recent literature contains several publications 
where whole-body FDG-PET has been used for the staging of malignant lymphoma. Few 
studies have compared FDG-PET with other imaging modalities, notably CT, for the 
staging of primary untreated malignant lymphoma. Moog et al prospectively evaluated 
the accuracy ofFDG-PET and CT in detecting nodal and extranodal involvement in 141 
patients with HD and NHL (66,67). They reported that FDG-PET is more accurate than 
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CT in nodal and extranodal staging of lymphoma. FDG-PET permitted the detection of 
additional lesions and changes in staging levels in 16% of patients with extranodal 
involvement and in 8% of patients with nodal disease. These results are in agreement 
with those of several other studies showing an equivalent or superior diagnostic 
efficiency of FDG-PET in staging patients with ,lymphoma prior to therapy, when 
compared to CT ( 68-70). In a retrospective study in 96 patients with NHL Spaepen et a! 
investigated the value of FDG-PET in detecting residual disease (71 ). The authors 
concluded that persistent uptake after first-line chemotherapy in NHL was highly 
predictive of residual or recurrent disease. Data from other studies indicate that whole-
body FDG-PET has higher diagnostic and prognostic value than classical CT scan 
imaging for posttreatment evaluation in HD as well as in NHL (69,70,72). In conclusion. 
whole-body FDG-PET is a very promising imaging modality in patients with malignant 
lymphoma. A practical problem of FDG-PET is its poor availability in some European 
countries. Further multicenter prospective studies are needed to determine its full 
potential for imaging of lymphoma. 
1.6 Somatostatin and somatostatin receptor scintigraphy 
Somatostatin (SS) was originally discovered as a hypothalamic neurohormone that 
inhibited growth hormone (GH) secretion. It was subsequently demonstrated that SS is a 
widely distributed peptide in both the central and peripheral nervous system and in 
various peripheral tissues throughout the body. In mammals, two forms of bioactive 
peptides, somatostatin 14 and somatostatin 28, are produced by tissue-specific proteolytic 
processing of a common precursor. SS acts on various targets including the cerebral 
cortex, pituitary, gut, endocrine and exocrine pancreas, thyroid and adrenals. SS has 
many different biological activities. It may act as a neurotransmitter (acting within the 
central nervous system), a neurohormone (inhibiting the release of the pituitary hormones 
GH and TSH), a classical hormone (secreted by the D-cells of the pancreatic islets into 
the portal vein) or a paracrine factor (mediating the influence of the D-cells on the A- and 
B-cells of the pancreatic islets). Its hormonal actions include the inhibition of the release 
of gro\Vth hormone. insulin. glucagon, gastrin, serotonin and calcitonin (73,74). The 
effects of SS are achieved following binding to and activation of high-affinity receptors, 
located with different densities in the SS target tissues. SS receptors (SS-Rs) are 
structurally related membrane glycoproteins. At this moment, five distinct genes for five 
subtypes of the human SS-R (hSSTRl-hSSTR5) have been cloned and pharmacologically 
characterized (75-78). 
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These SS-R subtypes belong to a superfamily of receptors with seven transmembrane-
spanning domains (Figure 1). All subtypes mediate their effects via inhibition ofadenylyl 
cyclase activity (79). All five SS-Rs bind to SS-14 and SS-28 with high affinity (Table 8). 
Table 8. Properties of human somatostatin receptor subtypes 1-5 
Somatostatin receptor 
Subtype 1 Subtype 2 Subtype 3 Subtype 4 Subtype 5 
Chromosomal location 14 17 22 20 16 
Selectivity of 
somatostatin analogs 
Somatostatin 14 + + + + 
Somatostatin 28 + + + + 
Octreotide ± ~ 
The therapeutic use ofSS is limited by its multiple actions and short plasma half-life of2-
3 minutes, requiring the cumbersome administration by continuous infusion for any 
clinical application. Therefore, studies have been initiated with the purpose of designing 
and synthesizing SS analogs with selective enhanced and prolonged activities. The SS 
analog octreotide was synthesized by the group of Bauer et al (80). Octreotide has a half-
life of 90-120 minutes when administered subcutaneously. Octreotide binds with high 
affinity to subtype 2 (hSSTR2) and subtype 5 (hSSTR5). The analog has a relatively low 
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affinity to hSSTR3 and shows no significant binding to hSSTRI and hSSTR4 (Table 8) 
(77, 78,8 I ,82). 
SS-Rs are expressed in normal as well as tumor tissues. A variety of human malignant 
tumors express SS~Rs (83). · SS-Rs have been found in most tumors originating from 
physiological SS-R positive tissues, i.e. pituitary tumors (84,85), endocrine gastro-
enteropancreatic tumors (86-88), and brain tumors (89-91). including meningiomas. 
astrocytomas and neuroblastomas. SS-Rs are also expressed in tumors originating from 
several other organs, i.e. medullary thyroid carcinomas (92,93), breast carcinomas 
(94.95), renal cell carcinomas (96) and paragangliomas (97). Most SS-R positive tumors 
are well differentiated or have neuroendocrine features. 
In 1987 peptide receptor scintigraphy using radiolabeled analogs of SS was introduced 
for tumor imaging (98.99). SS-R bearing neuroendocrine tumors could be visualized after 
intravenous administration of radioiodinated analogs of SS (98-100). However, [' 23!-
Tyr']-octreotide has several drawbacks for in vivo scintigraphy (101). 123! of high specific 
activity is expensive and not readily available worldwide. Radiolabeling and purification 
is time consuming, the physical half-life of the radionuclide is short and there is a rapid 
clearance from the blood resulting in a short effective residence time for accumulation in 
tumor tissue. Moreover, substantial accumulation of radioactivity is seen in the intestines. 
since [' 23!-Tyr']-octreotide is mainly cleared via the liver and biliary system. This makes 
the interpretation of planar- and SPECT images of the upper abdomen difficult. By and 
large these problems can be circumvented by substituting 123! with 11 1Indium bound to a 
chelated SS-analog (Figure 2). 
[ 111In-DTPA-D-Phe1]-octreotide (111 ln-pentetreotide) has certain notable advantages: easy 
preparation, general availability and appropriate half-life. Because of the longer half-life 
in the circulation of 111 In-pentetreotide the tumor tissue is exposed to the radionuclide for 
longer times, which improves gamma camera imaging 24 hours after injection. Moreover, 
because of its mainly renal clearance, faecal excretion of radioactivity amounts to only a 
few percent ofthe administered dose (102). Therefore, 111 ln-pentetreotide is very suitable 
for use in planar imaging and SPECT of the abdomen. This is especially of importance 
for the localization of tumors in the upper abdomen, which are obscured by radioactivity 
from other organs, e.g. kidney, spleen and liver. The clinical value of 111In-pentetreotide 
scintigraphy (SS-R scintigraphy) in the visualization of neuroendocrine tumors has been 
confirmed by various groups of investigators (1 03-1 09). 
SS-Rs are also present on cells derived from several hematological malignancies (110-
112). SS binding sites have been detected on acute lymphoblastic leukemia and acute 
myeloid leukemia (113). Activated lymphocytes and leukemic cells express SS-Rs of 
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Figure 2 Chemical structures of somatostatin, octrcotidc and [ 111 In-DTPA-D-Phc 1]-octrcotidc. 
high affinity, which suggests that SS-R expression is related to biological function of 
these cells (II 0-112). Many studies have demonstrated that SS has a modulatory effect on 
the immune system. SS and its receptors are expressed in human lymphoid organs and 
can regulate various immune functions including lymphocyte proliferation, 
immunoglobulin synthesis, and cytokine production (112). These findings have Jed us to 
explore whether it was possible to visualize NHL and HD in vivo. In a study in I 0 
patients with histologically proven malignant lymphoma SS-R scintigraphy was 
performed as part of the staging procedure. In all patients the lymphoma localizations that 
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were apparent following conventional evaluation could be confirmed by SS-R 
scintigraphy. Furthermore, in four patients additional lymphoma localizations were found 
through SS-R scintigraphy. In order to verifY that indeed SS-R expressing lymphoma 
tissue was visualized, in four cases tissue biopsies were taken. Subsequent in vitro SS-R 
autoradiography confirmed that the hot spots on the scans indeed consisted of SS-R 
positive lymphoma tissue (114). The presence of SS-Rs on malignant cells of lymphoid 
origin was further demonstrated by Reubi et al (ll4,ll5). by use of in vitro SS-R 
autoradiography. SS-Rs were found in NHL of low-grade, intermediate-grade, and high-
grade malignancy. In addition one tissue sample ofHD was SS-R positive. In these tissue 
specimens, a low to moderate density of receptors was observed. but some NHL of high-
grade malignancy expressed a high SS-R density. 
1. 7 Aim ofthe study 
As discussed above, SS-Rs are expressed by malignant lymphomas at high frequency and 
it is possible to visualize these lymphomas with SS-R scintigraphy. Anatomical imaging 
studies, like CT or MRI, suffer from various shortcomings (see paragraph 1.3). Some 
groups have reported their experience with SS-R scintigraphy in malignant lymphoma 
(Table 9 and Table 10) (114,116-122). 
Table 9. SS-R scintigraphy studies in Hodgkin's disease 
First-named Ref. Study Patient Therapy Sensitivity Sensitivity 
author no. per patient per site 
% % 
Bares (116) R 5 pre- and post therapy NA 78 
Van Hagen (114) p 2 pre therapy 100 100 
Bong (117) p 9 pre- and post therapy NA 91 
Sarda (118) p 3 pre therapy 100 67 
Lipp (119) p 11 pre- and post therapy 73 70 
Goldsmith (120) p 2 pre therapy 100 100 
Ivancevic (121) p 6 pre- and post therapy 57 57 
R. retrospective: P. prospective: );;A, not applicable. 
However, the numbers of patients in these studies have been small and studies in 
previously untreated patient populations have been relatively scarce. 
In this thesis we report on a series of studies that addressed the question of the clinical 
significance of SS-R scintigraphy in the staging of malignant lymphomas in a variety of 
clinical conditions. 
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Table 10. SS-R scintigraphy studies in non-Hodgkin~s lymphoma 
First-named Ref_ Study Patient Therapy Sensitivity Sensitivity 
author no. per patient per site 
% % 
Bares (116) R 13 pre- and post therapy NA 63 
Van Hagen (114) p 8 pre therapy 100 100 
Bong (117) p NA pre- and post therapy NA 37 
Sarda (118) p ?' 
-" 
pre therapy 91 57 
Lipp (119) p 23 pre- and post therapy 57 34 
Goldsmith (120) p 5 :'-!A 20 1\A 
Ivancevic (121) p 26 pre- and post therapy 85 38 
Lipp (122) R 10 pre therapy 70 48 
R, retrospective; P. prospective: NA not applicable. 
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SS-R SCINTIGRAPHY IN HODGKIN'S DISEASE 
Abstract 
Somatostatin receptor scintigraphy has been successfully used in the visualization of a variety 
of neuroendocrine tumors. In vin·o studies have shown that somatostatin receptors (SS-Rs) 
are present in human malignant lymphomas. We conducted a prospective study in 56 
consecutive untreated patients with histologically proven Hodgkin's disease (HD) and 
compared the results of SS-R scintigraphy with physical and radiological exantinations as 
initial evaluation. SS-R scintigraphy was positive in 55156 (98%) patients at sites of 
documented disease. In 20 patients SS-R scintigraphy disclosed lymphoma localizations not 
revealed following procedures of conventional staging. As a result in 12 patients (21 %) SS-R 
scintigraphy produced a change of stage and in seven patients (13%) the additional 
information obtained from SS-R scintigraphy led to a change of treatment. SS-R scintigraphy 
failed to visualize sites of HD in four patients. lllilinly in the abdominal area. In three patients 
a false-positive result was obtained. These data show that SS-R scintigraphy provides an 
imaging technique that appears to visualize tumors in most patients with HD and may be 
clinically useful in the management of these patients. 
Introduction 
Precise staging of the dissemination of the disease is critical in the treatment and prognosis of 
patients with Hodgkin's disease (HD). To detennine the extent of the disease, several imaging 
tecbn.iques are currently employed_ e.g. plain chest radiography, computed tomography (CT), 
sonography and lymphangiography (l ). TI1ese techniques are also used to assess the response 
of the disease at different sites to treatment. Gallium scintigraphy is variably used in the 
work-up of patients with HD (2). 
A variety of human neoplasms express somatostatin receptors (SS-Rs). SS-Rs have been 
found in neuroendocrine (3-5). breast (6,7) and brain tumors (8). In order to take advantage 
of SS-R tissue expression, radiolabeled somatostatin (SS) analogs have been applied to 
visualize SS-R positive tumors in vivo with a gamma camera. SS-R scintigraphy has proved 
clinically useful for refined tumor localization in patients with carcinoid tumors. pancreatic 
endocrine tumors and paragangliomas (9-12). 
SS-Rs are expressed on the membranes of human lymphoid cells, including malignant 
lymphoma and HD (13), as has become apparent from autoradiography of tissue sections. 
TI1ere is as yet only limited experience with SS-R scintigraphy in patients with HD (14-17). 
We set out to evaluate SS-R scintigraphy as a potentially useful method for in vivo imaging 
of tumor deposits in patients with HD. Here we present the results of a prospective study in 
56 newly diagnosed, previously untreated. patients with histologically proven HD. 
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Patients and methods 
Patients 
56 consecutive, newly diagnosed and previously untreated patients with histologically proven 
HD were enrolled in the study. The stage of the disease according to the Ann Arbor 
classification (!8) was established by conventional methods, which included a physical 
examination, chest radiography, CT of chest, abdomen and pelvis, bone marrow biopsy, and 
occasionally lymphangiography. All patients had given informed consent to the study, which 
was approved by the ethics committee of the University Hospital Rotterdam. 
Scintigraphy 
SS-R scintigraphy was performed after intravenous injection of the radioactive labeled SS 
analog C''ln-DTPA-D-Phe1]-octreotide (obtained from Mallinckrodt Medical BV, Petten, 
The Netherlands). The preparation of[111In-DTPA-D-Phe1]-octreotide, the dose administered 
(222 MBq) and the technique of scintigraphy with the gamma camera, as well as with single 
photon emission computed tomography (SPECT) have recently been described (!0,19-22). 
Planar total body scintigraphy was performed 24 h post-injection with a large-field-view 
gamma camera (Counterbalance 3700 and ROTA II; Siemens Gammasonics, Erlangen, Ger-
many) equipped with a medium-energy collimator. ln all patients SPECT images of the upper 
abdomen were made. For both planar and SPECT scintigraphy, images with a long exposure 
time were obtained, e.g. 15 min for planar views. Repeated scintigraphy of the abdomen was 
performed 48 h post-injection when 24-h scintigraphy showed accumulation in the abdomen. 
In normal individuals a physiological accumulation of radioactivity may be seen at 24 h after 
intravenous administration of [111 !n-DTPA-D-Phe1]-octreotide in the pituitary and thyroid 
gland, the liver, spleen, kidneys, the urinary bladder and occasionally in the gallbladder. The 
presence of intestinal radioactivity (mainly in the colon at 24 h) is due to some hepatobiliary 
clearance of [111In-DTPA-D-Phe1]-octreotide and may be reduced following the use of 
laxatives (20,21). The SS-R scans were evaluated by two investigators at the same time 
without !mowing patient identity or results of the conventional diagnostic work-up. Finally, 
the results of the SS-R scans and conventional diagnostic tests were compared by the study 
coordinator. ln case of discrepancies additional radiodiagnostic investigations were scheduled 
before the beginning of treatment and, if practically possible, cytological or histological 
verification was sought. ln nine patients SS-R scintigraphy was repeated after therapy. All 
patients were followed during and after treatment. 
Autoradiography 
In three patients SS-R autoradiography was performed on 10 micrometer thick cryostat 
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sections of the tumor samples, using a iodinated SS octapeptide analog [125!-Tyr3]-octreotide 
( 125!-204-090) as radioligand (3,4). 
Results 
The clinical characteristics of the 56 patients with HD in whom SS-R scintigraphy was 
performed are given in Table l. 
Table 1. Clinical features and SS-R scintigraphv results in 56 patients with HD 
Age (yr) 
Median 33.1 
Range 15-66 
Sex 
Female 29 (52%) 
Male 27 (48%) 
Histologic subtype 
Lymphocyte predominance 4(7%) 
::-.Jodular sclerosis 46 (82%) 
::v1ixed cellularity 6 (11 %) 
Clinical stage* 
Stage I 11(19%) 
Stage II 29 (52%) 
Stage III 7 (13%) 
Stage IV 9 (16%) 
SS-R scintigraphy results 
Positive 55 (98%) 
Nco-ativc 1 2% 
*based on physical examination and conventional staging methods. 
SS-R scintigraphy indicated SS-R positivity at areas of documented active disease in 55 cases 
(98%). Two examples of SS-R scintigraphy of lymphoma localizations above the diaphragm 
are shown in Figure lA (mediastinum) and Figure lB (neck). In Figures 2A-C a SS-R 
scintigram of multiple para-aorric abdominal lymph nodes is shown. 
Additional sites ofHD revealed by SS-R scintigraphy (20 patients) 
In 20 patients SS-R scintigraphy disclosed activity suggestive of lymphoma which had not 
been revealed following physical and radiological exantination. Table 2 lists the additional 
sites of disease as suggested by SS-R scintigraphy in comparison with the results of 
conventional staging in these 20 patients. 27 additional SS-R positive sites of disease became 
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A 
Figure I 
(A) Visualization of mediastinal lymph nodes (arrow) in a patient with stage IB HD. mi-..;:cd cellularity. by SS-R 
scintigraphy at 24 h (anterior image of the thora:'i:). On CT a large mediastinal mass of 11 x 9 em was shown. In this 
patient normal accumulation of radioactivity in the thyroid, not seen on this image, was apparent on the anterior image 
of the head and neck. (B) SS-R scintigraphy revc::tls positive supraclavicular lymph nodes in the neck (arrow) at 24 h in 
a patient with stage lA HD. mixed cellularity (anterior image of the head and neck). Normal accumulation of 
radioactivity is seen in the pituitary and thyroid. On physical examination a lymph node of 3 em diameter was palpa-
ted. 
apparent in these 20 patients. Most new localizations were above the diaphragm, i.e. in the 
neck (n ~ 12 cases), mediastinum (n ~ 3), axilla (n ~ 3), infraclavicular area (n ~ l) and lung 
(n ~ l ), but also in the para-aortic region (n ~ 5) and the inguinal area (n ~ 2). In patient l 0, 
following the results of SS-R scintigraphy, we confmned the presence of an abnormal lymph 
node in the neck on repeated palpation (1.5 em diameter). In the same patient multiple small 
intrapulmonal "lesions" were seen on CT, which were read as possible Hodgkin localizations. 
The intrapuhnonal lesions were negative on SS-R scintigraphy. After six cycles of chemo-
therapy no residual masses were seen. The radiographic intrapuhnonal abnormalities that had 
been SS-R negative had not changed and were retrospectively interpreted as pre-existent 
abnormalities of unclear nature (follow-up time 2 years). In the majority of patients additional 
investigations were performed to verifY the diagnosis at discrepant sites (see Table 2). The 
superiority of SS-R scintigraphy was confirmed in 12120 patients, i.e. by repeated palpation 
(n ~ 4), subsequent radiodiagnostic tests (n ~ 6) and/or cytopathology (n ~ 2).ln the latter 12 
patients the physical and radiological abnormalities disappeared following cytotoxic 
treatment (Table 2, follow-up). In nine patients SS-R scintigraphy was repeated after 
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Figurc2 
(A) SS-R scintigraphy in a patient with abdominal 
HD, nodular sclerosis. Planar anterior image of the 
abdomen at 48 h after injection of[ 1 ' 1In-DTPA-D-
Phc;J-octrcotide. Apan from normal accumulation 
of radioactivity in the liver (L) and kidney (K) an 
enlarged spleen (S) can be seen. -;-;etc the many 
sites of accumulation of radiolabdcd octrcotide 
(arrows). which represent para-aortic lymphoma 
localizations. (B/C) Abdominal SPECT 
transversal (B) and coronal (C) images of the same 
patient 24 h after injection of [1111n-DTPA-D-
Phc1}octrcotidc. Note the visualization of the liver 
(L). spleen (S) and kidneys (RK LK). Clearly 
prominent bot spots are seen medial/ventral to 
both kidneys in the para-aortic region (PAO). 
successful chemotherapy and in all patients SS-R scintigraphy had become entirely negative 
(Table 2, repeated SS-R scintigraphy). 
In 12 patients the discrepancies between SS-R scintigraphy and conventional staging 
procedures resulted in a change of Ann Arbor clinical stage. SS-R scintigraphy findings 
correctly upgraded the clinical stage in II cases and the clinical stage was correctly down-
graded in one patient. As a result the treatment plan was altered in seven patients. In all seven 
patients the superiority ofSS-R scintigraphy was supported by additional evidence. 
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Table 2. Additional sites of disease demonstrated following SS-R scintigraphy in 20/56 
patients with HD: a comparison between SS-R scintigraphy and conventional staging 
methods 
Pt Additional sites of disease Verification Repeated SS- Change 
(+ ~ HD) R scintigra);!hy clinical stage 
2 1\eck, para-aortic ~ CT, follow-up ND II~ III 
4 1\eck 1\'D ND No 
5 ~eck +Cytology, follow-up ND No 
6 Neck + Phys: exam., follow-up ND No 
8 Neck, mediastinum -c CT, follow-up ND I~ II 
10 Neck, lung negative + Phys. exam., follow-up ND IV~ II 
13 Para-aortic + Yes II _, III 
14 Neck ND ND No 
17 Neck + Sonography, follow-up ND No 
20 Mediastinum, axilla, lung Yes III _, IV 
25 Para-aortic ND ND II~III 
27 Infraclavicular + CT, follow-up ND I~ II 
28 Neck. mediastinum + CT, follow-up ND I~ II 
29 Neck + Yes No 
33 Neck, axilla. inguinal --l- Phys. exam., follow-up Yes No 
35 Neck + Yes I~ II 
44 Axilla + Phys. exam., follow-up Yes No 
50 Para-aortic + CT, follow-up Yes II~ III 
52 Para-aortic + Yes II~ III 
55 Ingginal +Histology. follow-ui! Yes u~ III 
::\D. not done: Phys. exam., physical examination. 
False-negative results ofSS-R scintigraphy (four patients) 
In four patients SS-R scintigraphy did not show localizations, which had become apparent 
following radiological methods (see Table 3). In patients 3, 7 and 26 enlarged abdominal 
para-aortic lymph nodes visualized on CT and lymphangiography were not apparent on SS-R 
scintigraphy images. The largest non-visualized lesion in the abdominal area had a diameter 
of 4.5 em. In all three patients the enlarged para-aortic lymph nodes disappeared after 
treatment. In the fourth patient (no. 40), SS-R scintigraphy demonstrated a normal-sized 
spleen with a homogenous distribution of radioactivity, but CT and sonography showed a 
spleen of normal size with multiple hypodense areas, which disappeared following 
chemotherapy. In these four patients in whom SS-R scintigraphy missed certain localizations 
of HD, the clinical stage, if based on SS-R scintigraphy only, would have been underesti-
mated in one individual. 
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Table 3. False-negative SS-R scintigraphy in 4/56 patients with HD: a comparison between 
SS-R scintigra~hv and conventional staging methods 
Pt Sites of disease: Clinical stage: Sites of disease: Clinical 
conventional methods conventional SS-R scintigraphy stage: 
methods SS-R 
scintif!fa hv 
3 Left neck, mediastinum, IV Left neck. mediastinum, IV 
lung. para-aortic lung 
7 Left neck, mediastinum, III Left neck, mediastinum II 
para-aortic 
26 Mediastinum, para- III Left neck, mediastinum, III 
aortic, spleen spleen 
40 Mediastinum, para- III Mediastinum. para-aortic, III 
aortic. left para-iliac, left para-iliac, left inguinal 
left inguinaL s leen 
Spleen and abdomina/lymph node involvement with HD 
What about tbe performance of SS-R scintigraphy witb regards to abdominal involvement 
witb HD? The spleen was enlarged in seven patients according to CT and sonography. In five 
oftbese individuals multiple hypodense areas were also apparent (see Table 4). In all seven 
patients SS-R scintigraphy showed an enlarged spleen witb a homogenous distribution of 
radioactivity. In an eighth patient (no. 40), where CT and sonography showed multiple 
hypodense areas in a normal-sized spleen, tbe spleen appeared normal on SS-R scintigraphy. 
Therefore, SS-R scintigraphy failed to demonstrate spleen involvement in one patient. 
Enlarged abdominal para-aortic lymph nodes were seen on CT and lymphangiography in 
eight patients, five of whom were also SS-R scintigraphy positive (see Table 4). 
Table 4. Abdominal lymph node or spleen involvement in HD: a comparison between SS-R 
scintigraphY and conventional staging methods (CSl\f) 
Sites of disease SS-R scintigraphy SS-R scintigraphy -
Para-aortic 
Spleen 
Total 
/CSM ~ /CSM 7 
5 
7 
12 
3 
4 
SS-R scintigraphy + 
/CS:v!-
5 
0 
5 
SS-R scintigraphy, somatostatin receptor scintigraphy; CSM. conventional staging methods; SS-R 
scintigraphy =ICSM =:abnormalities visualized by SS-R scintigraphy and CSM; SS-R scintigraphy -/CSYI +: 
abnormalities visualized only by CSM: SS-R scintigraphy -/CSM -: abnormalities visualized only by SS-R 
scintigraphy. Numbers indicate patients with para-aortic or spleen abnormalities that were evident on SS-R 
scintigraphy and CSM. 
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The smallest lymphoma within the abdomen demonstrated by SS-R scintigraphy had a 
diameter of approximately 2.0 em. In five other patients para-aortic lymph nodes were 
visualized on SS-R scintigraphy that had not been detected on CT and lymphangiography. In 
three of these five patients the para-aortic SS-R positive lesions disappeared after chemothe-
rapy. In the other two patients SS-R scintigraphy was not repeated. One patient had enlarged 
para-iliac lymph nodes on CT and these were also visualized by SS-R scintigraphy. 
False-positive results ofSS-R scintigraph;v (three patients) 
In three patients the positivity on SS-R scintigraphy on selected sites clearly was not related 
to localizations ofHD (see Table 5). 
Table 5. False-positive SS-R scintigraphy in 3/56 patients with HD: a comparison between 
SS-R scintigraphv and conventional staging methods 
Pt Sites of disease: Clinical stage: Sites of disease: Reason false-
conventional conventional SS-R scintigraphy positive SS-R 
methods methods scintigraphY 
42 Right neck, II Right neck, left/right Ethmoidal 
left/right axilla. axilla. mediastinum, sinusitis 
mediastinum nasal region 
46 Left neck, II Left neck, mediastinum. Hematoma 
mediastinum anterior iliac spine 
49 Left/right neck, II Left/right neck, Common cold 
mediastinum mediastinum, 
nasal reaion 
In two patients accumulation of radioactivity was observed in the nasal region. A sinusitis in 
one patient and a common cold in the other patient had caused the positive scan. The third 
patient showed abnormal accumulation of radioactivity in the anterior iliac spine after a bone 
marrow biopsy at that site. 
Further results ofSS-R scintigraphy and SS-R autoradiographJ' 
In 28/55 SS-R positive patients the results of SS-R scintigraphy and conventional staging 
methods were concordant. The sites of disease and clinical stages are summarized in Table 6. 
The smallest lymph node identified by SS-R scintigraphy located in the neck had a diameter 
of 1.0 em. The only patient with an entirely negative SS-R scintigraphy had stage !VB HD 
with lymph nodes in the axilla and an infiltrated bone marrow. 
Finally, side effects were not noted in any of the patients following the administration of 
[ 111 ln-DTPA-D-Phe1]-octreotide for SS-R scintigraphy. 
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Table 6. Concordance between SS~R scintigraphy and conventional staging methods in 
28/56 patients with HD 
No. of patients 
13 
4 
4 
2 
Sites of disease 
Neck. mediastinum 
1\eck 
1\eck, axilla, mediastinum 
Mediastinum 
Clinical stage 
II 
II 
Neck, bone marrow* IV 
Neck. axilla, mediastinum, para-aortic III 
Neck. mediastinum, para-aortic. spleen III 
Neck. mediastinum, lung IV 
Neck. axilla, inguinal. mediastinum, para- IV 
aortic. s leen. luno-
*bone marrow involvement not apparent on SS..R scintigraphy. 
In three patients SS-R analysis was performed on surgically removed lymph nodes. 
Autoradiographic investigation confirmed the presence of specific SS-Rs in the tissue 
biopsies of malignant lymphoma in these individuals (Figures 3A-C). These lymph nodes 
were all positive in vivo on SS-R scintigraphy. 
Discussion 
The accuracy of staging is a cornerstone of the treatment of patients with HD. Clearly) current 
staging is still highly inadequate. For instance, stage I and II patients considered at high risk 
of failure are frequently treated with systemic chemotherapy. For this purpose, in stages I and 
II, clinical prognostic factors are employed to select between locoregional or systemic 
therapy. Following treatment it may be difficult to distinguish between persisting active HD 
or fibrotic abnormalities, e.g. in case of residual radiological mediastinal masses still apparent 
following chemotherapy. 
In the present study we employed SS-R scintigraphy in 56 consecutive patients with 
histologically proven HD. Among these, 98% of the patients showed a positive SS-R scan. 
SS-R positive localizations were apparent at different sites of active disease above and below 
the diaphragm. Since the pathophysiological basis of SS-R scintigraphy staging bears no 
relationship with that of the other diagnostic imaging techniques, SS-R scintigraphy appears 
to provide an independent approach to the evaluation of the dissemination ofHD. Therefore 
SS-R scintigraphy may add essential information to the results of the complete staging 
process. The discrepancies between the results ofSS-R scintigraphy and conventional staging 
work-up as reported here support this. In only 28 patients was complete concordance 
apparent between SS-R scintigraphy and physical examination, X-ray examination, CT 
scanning and lymphangiography. 
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Figure 3 
(A) 
Somatostatin receptors in a 
ca.~ of Hodgkin's lymphoma 
Haematoxylin-eosin-stained 
section. Bar"" I mm. 
(B) 
Autoradiogram showing 
total bin<ling of '"I-[Tyi']-
octrcotidc. 
(C) 
Autoradiogram showing 
nonspecific binding of 
1zsl-[Tyr3]-octrcotide (in 
presence of 1 0~ of 
unlabeled [Tyr')-octreotide). 
Autoradiography demonstrated the presence of SS-Rs in the lymphoma tissues surgically 
removed from three patients with HD. [' 11In-DTPA-D-Phe1]-octreotide and [1251-Tyr3]-
octreotide bind with high affinity and specificity to the same receptor (19). The identification 
of SS-Rs in vitro in biopsies from the lymph nodes with HD, confirms that the activity seen 
so 
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in vivo actually represented SS-R positive tumor tissue. In patients with histologically proven 
HD, the tumors display SS-Rs of high enough affinity and density to apparently permit 
external imaging by the radio labeled SS analog in most cases. 
In 20 patients SS-R scintigraphy disclosed lesions not revealed following a variety of 
radiodiagnostic procedures. In most of these individuals additional investigations were 
undertaken in an effort to verifY the diagnosis ofHD at sites of discrepancy. 
SS-R scintigraphy failed to demonstrate certain sites of HD in four cases and SS-R 
scintigraphy was entirely negative in one individual with extensive involvement of HD. In a 
significant proportion of cases the clinical stage as defined by conventional staging methods 
changed following consideration of the results of SS-R scintigraphy. In II cases of the entire 
series of 56 subjects the disease was upgraded to a higher stage. The additional information 
ofSS-R scintigraphy resulted in a different choice of therapy in seven patients (13%). 
As compared with conventional staging methods, SS-R imaging offers a number of distinct 
advantages. First, because the whole body is imaged, localizations in areas not under clinical 
suspicion can be evaluated, and therefore the full extent of the disease more accurately 
documented. Second, after treatment with chemo- or radiotherapy, residual or recurrent 
tumors of malignant lymphomas remain SS-R positive (13). SS-R scintigraphy may be 
potentially useful to assess remission and avoid 'over treatment' in patients in remission. SS-
R scintigraphy may also be of use in the management of residual masses, including the 
notoriously difficult mediastinal localizations. Our preliminary experience in two patients 
with primary resistant HD gives some support that this may be true (data not shown). After 
six cycles of chemotherapy, a residual mass was seen on CT in the mediastinum in one 
patient and in the para-aortic region of the abdomen in the second. SS-R scintigraphy was 
positive in these areas in both patients. Histologic confirmation of active HD at the latter sites 
was obtained in both patients. We are presently investigating the role of SS-R scintigraphy in 
the evaluation of treatment response in patients with HD in a prospective study. 
In the abdominal region SS-R scintigraphy (unlike conventional techniques) revealed para-
aortic lymph nodes in five patients. A repeated SS-R scintigraphy after chemotherapy in three 
of these patients showed total disappearance of the lesions. In 12 cases there was complete 
agreement between the results of SS-R scintigraphy and conventional radiodiagnostic techni-
ques in the detection of abdominal sites ofHD. SS-R scintigraphy failed to detect abdominal 
HD in four patients. Para-aortic lymph nodes were missed in three patients and spleen invol-
vement was not apparent on SS-R scintigraphy in one patient Thus, all false-negative cases 
of our series were located in the abdomen. This problem was also seen in patients with 
carcinoid tumors where planar images of SS-R scintigraphy failed to detect some liver meta-
stases (12). The visualization of abdominal lymphoma locali7..ations with [111ln-DTPA-D-
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Phe1]-octreotide may be limited by a number of factors. The human spleen expresses high-
affinity SS-Rs (23). Frequently lymphoma metastases in the spleen appear to accumulate a 
similar amount of radioactivity as does surrounding normal spleen tissue. After intravenous 
injection, [111ln-DTPA-D-Phe1]-octreotide is rapidly cleared from the blood, predominantly 
excreted via the kidneys, and a minority of the isotope removed by hepatobiliary clearance 
(20). The hepatobiliary clearance results in hepatic and intestinal accumulation of radio-
activity. The presence of intestinal radioactivity can usually be overcome by the use of 
laxatives. Nevertheless, in some patients radioactivity may remain in the colon and this may 
interfere with the detection of para-aortic lymph nodes. The physiological uptake of 
radioactivity in the liver. although less than in the spleen, may reduce optimal detection of 
liver involvement with SS-R positive tumors. Overprojection of radioactivity of the liver, 
spleen and kidneys can hide positive lesions in lymph nodes on the planar images. The use of 
SPECT images of the upper abdomen in part may overcome this problem and is therefore 
recommended for the localization of abnormal lymph nodes in the spleen and liver hilar 
areas. The same is true for the para-aortic region of the upper abdomen. 
SS-R scintigraphy is not specific for visualizing tissue involved with HD. Granulomatous 
diseases, autoimmune diseases and neuroendocrine tumors may result in positive SS-R scin-
tigraphy images as well (21,24). Obviously, therefore. SS-R scintigraphy cannot be used to 
diagnose malignant lymphoma. In this respect, SS-R scintigraphy shares the general 
limitations of most imaging techniques. In our study three false-positive results were seen. In 
two cases the positivity in the nasal region on the scan was caused by an infection; clinically, 
these t\vo patients had a common cold. Tills transient accumulation in the nasal region during 
the typical season of epidemic common cold/influenza is a well-known pitfall in the correct 
interpretation of SS-R scintigraphy (21). The third patient showed accumulation of 
radioactivity in the pelvis after bone marrow biopsy. Clinically a large hematoma was 
apparent. Our accumulated experience in more than a thousand patients has taught us that 
radioactivity may accumulate at sites of recent operation. 
In several centers gallium scintigraphy is used in the work-up of HD patients. Gallium 
scintigraphy is performed prior to therapy to provide information on the gallium avidity of the 
tumor at baseline. Current evidence would indicate that the sensitivity of gallium scintigraphy 
in the initial staging of patients with HD is in the order of 66-85% (25,26). The most impor-
tant value of gallium scintigraphy is therefore not in the initial staging of patients with HD but 
rather in the evaluation of lymphoma after treatment (2). It would be of interest to compare 
SS-R scintigraphy and gallium scintigraphy in the staging ofHD in funne studies. In this age 
of financial restraint these imaging techniques should be cost-effective. In Rotterdam a 
prospective cost-effective study is currently in progress that includes ultrasonography, com-
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puted tomography, gallium scintigraphy and SS-R scintigraphy. 
In conclusion, SS-R scintigraphy provides a useful method of diagnostic evaluation of 
patients with HD. It is a relatively easy and harmless procedure. Obviously, further 
prospective studies in larger groups of patients. both pre- and post-treatment, will be needed 
to fully define its value and place in the management of patients with HD. 
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SS-R SCINTIGRAPHY IN CUTANEOUS NHL 
Abstract 
Lymphoid cells may express somatostatin receptors (SS-Rs) on their cell surface. 
Therefore radiolabeled somatostatin analogs may be used to visualize SS-R positive 
lymphoid neoplasms in vivo. Exact staging is the basis for treatment decisions in 
cutaneous malignant lymphoma. We considered the possibility that SS-R scintigraphy 
might offer a clinically useful method of diagnostic imaging in patients with cutaneous 
malignant lymphoma. We evaluated SS-R scintigraphy in comparison with conventional 
staging methods in the staging of cutaneous malignant lymphoma. We conducted a 
prospective study in 14 consecutive patients with histologically proven cutaneous 
malignant lymphoma. SS-R scintigraphy was compared with physical, radiologic, and 
bone marrow examinations. Lymph node excisions were performed in patients with 
palpable lymph nodes. SS-R scintigraphy was positive in the lymph nodes in all four 
patients with malignant lymph node infiltration and negative in the three patients with 
dermatopathic lymphadenopathy. In two patients, previously unsuspected lymphoma 
localizations were visualized by SS-R scintigraphy. In only three patients all skin lesions 
were visualized by SS-R scintigraphy; these three patients had not been treated with 
topical corticosteroids. SS-R scintigraphy failed to detect an adrenal mass in one patient 
and bone marrow infiltration in two patients. SS-R scintigraphy may help distinguish 
dermatopathic lymphadenopathy from malignant lymph node infiltration in patients with 
cutaneous malignant lymphoma. 
Introduction 
Primary cutaneous lymphomas represent a group of non-Hodgkin's lymphomas (NHL) 
with involvement of the skin. Cutaneous T -cell lymphomas (CTCLs) are more common 
than cutaneous B-cell lymphomas (CBCLs) (!). The most frequent type of CTCL is 
mycosis fimgoides. Sezary syndrome occurs relatively rarely. CTCLs other than mycosis 
fimgoides/Sezary syndrome represent approximately 30% of all CTCLs and are large-cell 
lymphomas with pleomorphic, inununoblastic, or anaplastic features (! ). The malignant 
cell in mycosis fimgoides and Sezary syndrome is a T lymphocyte, which expresses 
phenotypic and fimctional characteristics of helper/inducer T cells (2,3). The clinical 
expression of CTCL varies greatly. The disease is slowly progressive after a long initial 
phase and eventually may progress to involve lymph nodes, visceral organs, and 
peripheral blood or bone marrow ( 4,5). 
Once the diagnosis of CTCL has been made the patient undergoes staging procedures to 
estimate the anatomic extent and localizations of the malignant process. The assessment 
of the extent is critical because the stage of disease is the most important prognostic 
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factor in patients with CTCL and may determine the choice of therapy (6-1 0). The role of 
diagnostic imaging in the staging of CTCL is not well established. Only a few reports 
describe the use of imaging modalities in the staging of CTCL (9,11-18). 
Somatostatin is a peptide hormone consisting of 14 amino acids. It is present in the 
hypothalamus, the cerebral cortex, the brain stem, the gastrointestinal tract, and the 
pancreas. Somatostatin receptors (SS-Rs) have been found on normal human lymphoid 
tissues (19,20). High-affinity SS-Rs have been identified in NHLs with the use of in vitro 
receptor autoradiographic techniques (21 ,22). On the basis of these observations, the 
radiolabeled somatostatin analog [111 In-DTPA-D-Phe1}octreotide has been applied 
clinically to visualize NHLs in vivo, with no toxicity (21-24). 
We describe the results of a prospective study comparing SS-R scintigraphy with 
conventional staging methods in 14 patients with CTCL and CBCL. 
Patients and methods 
Patients 
Between 1991 and 1994, 14 consecutive patients with histologically proven CTCL (n ~ 
II) and CBCL (n ~ 3) underwent staging evaluation. The stage of the disease was 
established by physical examination; whole body mapping of lesions; chest radiography: 
computed tomography (CT) of chest, abdomen, and pelvis; bone marrow aspiration and 
biopsy; and analysis of blood smears. CT scanning was performed with contiguous I 0 
mm axial sections after oral and intravenous administration of contrast material. Lymph 
node excisions were performed in patients with palpable lymph nodes. 
Mycosis fungoides was staged according to a staging classification of Fuks (7,12), 
modified by the Dutch Cutaneous Lymphomas Working Group as follows: stage 1: skin 
involvement only; stage II: skin and dermatopathic lymphadenopathy; stage Ill: skin and 
pathologic lymph nodes; stage IV: skin and visceral organ involvement. Every stage was 
subdivided into (a) limited plaques <10%, (b) generalized plaques >10%, (c) cutaneous 
tumors, and (d) generalized erythroderma. 
The study had been approved by the Ethics Committee of the University Hospital 
Rotterdam. 
Scintigraphy 
SS-R scintigraphy was performed after intravenous injection of the radioactive-labeled 
somatostatin analog [111ln-DTPA-D-Phe1]-octreotide (Mallinckrodt Medical BV, Petten, 
The Netherlands). The preparation of [111ln-DTPA-D-Phe 1]-octreotide, the dose 
administered (2: 200 MBq), and the technique of scintigraphy with the gamma camera, as 
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well as with single photon emission computed tomography (SPECT) have recently been 
described (23,25). Planar total body scintigraphy was performed 24 h after injection with 
a large-field-of-view gamma camera (Counterbalance 3700 and ROTA II; Siemens 
Gaffirnasonics, Erlangen, Germany) equipped with a medium-energy collimator. 
Repeated scintigrams were performed 48 h after injection when accumulation of 
radioactivity in the abdomen was observed on the 24-h scintigrams. In all patients SPECT 
images of the upper abdomen were made. In· normal persons a physiologic accumulation 
of radioactivity may be seen in the pituitary and thyroid glands, liver. spleen, kidneys, 
urinary bladder, and occasionally in the gallbladder. The presence of intestinal 
radioactivity (mainly in the colon at 24 h) is caused by some hepatobiliary clearance of 
C 11In-DTPA-D-Phe1]-octreotide and can be reduced by the use of laxatives (25.26). TI1e 
scans were evaluated by two investigators (EPK and HYO) who did not know the identity 
of the patients or the results of the conventional staging procedures. Finally the results of 
SS-R scintigraphy and conventional diagnostic tests were compared by the study 
coordinator (PJvdAL). In case of discrepancies additional radiodiagnostic investigations 
were scheduled, and if practical and possible, histologic verification was attempted. All 
patients were observed during and after treatment. In three patients SS-R scintigraphy 
was repeated during follow-up. 
Results 
The clinical characteristics of the 14 patients with CTCL (n ~II) and CBCL (n ~ 3) in 
whom SS-R scintigraphy was performed are given in Table I. Ten of 14 patients had 
been treated for long periods with topical corticosteroids. 
Patients with CTCL 
SS-R scintigraphy was positive m 5 of 11 patients with CTCL. The results of the 
comparison between the sites of disease demonstrated by SS-R scintigraphy and the 
conventional staging methods are summarized in Table l. 
SA.in evaluation 
CTCL was limited to the skin in 6 of 11 patients. In five of these six patients (i.e .. two 
patients with pleomorphic CTCL [patients 1 and 2] and three patients with mycosis 
ftmgoides [patients 5, 6, and II]), SS-R scintigraphy was negative. The skin lesions in 
these patients were macules or plaques. Patient 3 initially had limited plaques of 0.5 to I 0 
em diameter on multiple sites of the skin. Only one of these lesions was visualized on SS-
R scintigraphy. 
6! 
'"' 
Table 1. Clinical characteristics and comparison between somatostatin rcccptol' scintigraphy and conventional staging methods in 14 0 
"' ~ patients with cutaneous malignant lymphoma 
" 
'""' Pt Sex/ Diagnosis Time Time after Previous Stage Disease sites by Disease sites by SS-R !:]
"' no. Age between first treatment * conventional scintigraphy (yr) diagnosis symptoms methods 
and entry (yr) 
into study 
(mo) 
F/67 CTCL: I 4.0 TC Skin:macules on total Skin negative 
pleomorphic, skin and urticaria 
medium/large 
2 F/84 CTCL: l 0.3 None Skin: ulcers and Skin negative 
pleomorphic, plaques, erythema on 
small/medium legs 
3 M/52 CTCL: 2 2.0 PUVA Skin: limited plaques Skin positive (only 
pleomorphic, TC DLA (axilla, arm) 
mcdhun/large inguinal) DLA negative 
4 M/58 CTCL: l 1.5 TC Skin: erythroderma Skin negative 
pleomorphic, Lymph nodes (axilla, Lymph nodes 
medium/large inguinal) positive 
5 F/54 CTCL:MF l 8.0 TC Ia Skin: plaques Skin negative 
6 M/67 CTCL:MF l 7.0 TC Ib Skin: plaques Skin negative 
7 M/66 CTCL: MF 45 9.0 TC !Vb Skin: ulcers and Skin negative 
UVB plaques DLA negative 
DLA (neck, axilla, Synovia positive 
inguinal) 
8 F/61 CTCL: I 5.5 TC Skin: crythrodenna Skin negative 
SE:zary Lymph nodes Lymph nodes 
syndrome (inguinal) positive 
BM BMnegativc 
9 M/67 CTCL:MF I 0.8 None IVc Skin: tumors Skin positive 
Lymph nodes Lymph nodes 
(inguinal) positive 
Adrenal region Adrenal region 
negative 
10 M/71 CTCL: MF I 20 TC1 lid Skin: erythroderma Skin negative 
DLA (axilla, DLA negative 
inguinal) 
II F/58 CTCL:MF I 1.0 TC Ib Skin: macules Skin negative 
"' ~ 
12 F/76 CBCL I 0.7 None Skin: ulcers on leg Skin positive "' n 
and hips lvlediastinum '2 
positive g 
~ 
13 M/67 CBCL 2 0.4 Nonet Skin: nodule on neck Skin positive " 
'" >< z 
n 
14 F/74 CBCL 2 1.0 TC, ILC Skin: plaques around Skin negative c: 
>-l 
eye ~ 
'" B.~·I, bone marrow; CBCL, cutaneous B-ee!] lymphoma; CTCL, cutaneous T-eelllymphoma; DLA, dcnnatopathic lymphadenopathy; F, female; ILC, intralcsionnl 0 c 
corticosteroid; M, male; MF, mycosis fungoidcs; TC, topical corticosteroid; *staging according to the Dutch Cutaneous Lymphomas Working Group (modified from "' 
"' 
Fuks) (7 ,12); tconcomitant disease actinic reticuloid treated with prednisone; tconeomitant disease dermatitis hcrpctifom1is treated with dnpsone. ~ 
"' 
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Five of 11 patients had CTCL in a more advanced stage. In only one of these patients 
were the skin lesions shown by SS-R scintigraphy. Tbis patient (l\'o. 9) had multiple, 
sharply marginated, erythematous tumors on the skin of the face and back (Figure 1). 
A B 
Figure I 
(A) Patient with mycosis fungoidcs. multiple tumors on faee.(B) Same patient. left lateral planar view of head 
and neck. Normal accumulation of radioactivity in the thyroid. Skin tumors clearly visualized (arrows}. 
L_vmph node evaluation 
The results of physical examination, CT scanning. and SS-R scintigraphy in relation to 
lymph node histology are summarized in Table 2. In six patients, diseased lymph nodes 
of 1.5 to 3 em in diameter were palpable at physical examination. Five of these patients 
had generalized lymphadenopathy. These enlarged lymph nodes were all apparent on CT 
scan. In three patients SS-R scintigraphy was negative in the lymph node areas (patients 
3, 7, and 10). Lymph node excisional biopsy specimens in these three patients showed 
dermatopathic lymphadenopathy. SS-R scintigraphy was positive in the lymph node areas 
in the other three patients (patients 4, 8, and 9; Figure 2). The lymph node excisional 
biopsy specimens in these three patients confirmed the involvement of malignant 
lymphoma. The sensitivity and specificity of the CT scan for malignant lymph node 
infiltration were I 00% and 67%, respectively. The sensitivity and specificity of SS-R 
scintigraphy for malignant lymph node infiltration were I 00% and I 00%, respectively. 
In the 14 patients no lymphadenopathy in the thorax or abdomen was seen on CT scans of 
chest, abdomen, and pelvis or by SS-R scintigraphy. 
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Table 2. Results of physical examination, CT scan, and SS~R scintigraphy in relation with 
lymph node histologic findings in 14 patients with cutaneous malignant lymphoma 
Patient Physical CT scan SS-R scintigraphy 
no. examination lymph node lymph node 
lymph node diameter (em) areas 
diameter 
(em) 
3 3 Positive* 
2 Negative Negative Negative 
3 1.5 2 Negative 
4 2-3 2-3 Positive 
5 Negative Negative Negative 
6 Kegative ND Negative 
7 2 1.5-2 Negative 
8 2-4 2-4 Positive 
9 2 1.8 Positive 
10 3 3 Negative 
11 Negative Negative Negative 
12 Negative Negative Negative 
13 ~egative Negative Negative 
14 ~egative 1\egative Negative 
CT. comput~d tomography: );"0, not done: SS~R. somatostatin receptor 
*Result ofSS~R scan during follow~up. 
A 
Figure 2 
Lymph node 
histologic findings 
Malignant infiltration 
)ill 
Dermatopathic 
lymphadenopathy 
Malignant infiltration 
ND 
ND 
Dermatopathic 
lymphadenopathy 
Malignant infiltration 
Malignant infiltration 
Dennatopathic 
lymphadenopathy 
ND 
ND 
ND 
ND 
(A) CT scan of the thorax of patient with pleomorphic CTCL shows multiple enlarged lymph nodes (1.5 to 2 em 
in diameter) in the a."(illary regions (arrows). Lymph node excision biopsy specimen showed malignant 
lymphoma infiltration. (B) Same patient, anterior planar thoracic image. Normal accumulation of radioactivity 
in the thyroid and spleen~ abnormal accumulation in the axilla (arrow). 
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Organ evaluation 
Dissemination of CTCL to visceral organs or bone marrow was seen in three patients. 
Patient 7 had a seronegative arthropathy affecting the hands and wrists. SS-R 
scintigraphy was positive in multiple joints (hands, wrists, elbows, knees, and ankles). A 
synovial biopsy specimen showed an infiltrate of lymphocytes (exclusively T 
lymphocytes) and plasma cells in a reactive pattern. T -cell receptor gene rearrangement 
analysis was performed on skin and synovial specimens, and identical clonal T -cell 
populations were detected in both (data not shown). Bone marrow infiltration with Sezary 
cells (15%) was seen in patient 8 but was not apparent on SS-R scintigraphy. CT 
scanning demonstrated a large adrenal mass (5 to 7 em) in patient 9. Cytologic exam-
ination of a needle aspiration specimen of the adrenal mass confirmed infiltration with 
CTCL. SS-R scintigraphy was negative in this area. 
SS-R scintigraph}' during follow-up 
In three patients with pleomorphic CTCL, SS-R scintigraphy was repeated during follow-
up. Patient !, with initially negative SS-R scarming, was treated with PUV A therapy. 
Sixteen months later progressive skin disease had developed as well as lymph node and 
bone marrow infiltration with CTCL. SS-R scintigraphy was positive in the peripheral 
lymph node areas, but remained negative in the skin and bone marrow. In patient 2 a 
complete remission was reached after CHOP chemotherapy. Eleven months later the skin 
disease recurred (ulcers and plaques). SS-R scintigraphy was again entirely negative. The 
skin disease in patient 3, originally showing positivity on SS-R scintigraphy, recurred 
(tumors at multiple sites) 8 months after PUVA therapy and local radiotherapy. On SS-R 
scintigraphy some skin lesions were positive and some were negative. The patient did not 
respond to different types of chemotherapy and local radiotherapy. SS-R scintigraphy 
performed a third time revealed all active skin lesions (tumors). 
Patients with CBCL 
SS-R scintigraphy was positive in two ofthree patients with CBCL (Table 1). The skin 
lesions were visualized by SS-R scintigraphy in two patients. In patient 12, SS-R 
scintigraphy also revealed a previously unsuspected localization in the mediastinum 
(Figure 3A). On roentgenography and CT of the thorax (Figure 3B) no abnormalities 
were seen. However, this patient had radiologic evidence of mediastinal lymphoma 6 
months later. Mediastinal lymphoma involvement with pericardia} infiltration was con-
firmed at autopsy. In patient 13 the accumulation of radioactivity in the neck 
66 
SS-R SCINTIGRAPHY IN CUTANEOUS NHL 
A B 
Figure 3 
(A) Anterior thoracic planar image in patient with CBCL revealed previously unsuspected lymphoma in 
mediastinum (arrow). Normal uptake of labeled octrcotidc is seen in the thyroid, liver and spleen. (B) Same 
patient CT scan of the thora.'{, no abnormalities were seen. 
corresponded to a clinically evident skin nodule (2 em) in the neck. SS -R scintigraphy 
was entirely negative in the third patient. 
Side effects were not noted in any of the patients after the administration of [ 111 In-DTPA-
D-Phe1]-octreotide for SS-R scintigraphy. 
Discussion 
The prognosis and treatment of patients with CTCL depend on accurate staging. The 
staging system for CTCL considers the extent of skin involve men!, presence of lymph 
node or visceral disease. and detection of abnormal cells in the peripheral bl ood. In 
autopsy series, more than 70% of patients with CTCL have extracutaneous lesions that 
may involve nearly any organ (6.27)28). Despite the high incidence of extracutaneous 
CTCL found at autopsy, clinically overt extracutaneous disease, other than th at involving 
peripheral lymph nodes and blood, is uncommon. 
In the present study, we employed SS-R scintigraphy in II patients with histologically 
proven CTCL and three patients with CBCL. Among these. eight showed a positive SS -R 
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scan. SS-R positive localizations were apparent at different sites of active disease in the 
skin and in extracutaneous disease. 
Extracutaneous disease in CTCL is frequently found in lymph nodes. Histologic 
interpretation of lymph nodes in CTCL is sometimes difficult. Unlike the nodes in B-cell 
lymphomas, most often the nodal architecture is preserved and lymph nodes are rarely 
totally replaced by malignant T cells. Furthermore, patients with CTCL frequently have 
benign reactive lymphadenopathy or dermatopathic lymphadenopathy. In dermatopathic 
lymphadenopathy the paracortical T -cell zones may contain focal accumulations of 
atypical convoluted T lymphocytes. Southern blot analysis of the T -cell receptor gene has 
provided evidence of CTCL infiltration in dermatopathic lymph nodes (29,30). Patients 
with malignant lymph nodes tend to have a shorter survival than patients with 
dermatopathic lymphadenopathy (9,31). If malignant lymph node infiltration is apparent, 
patients are usually treated with systemic chemotherapy. This is in contrast to patients 
with dermatopathic lymphadenopathy to whom chemotherapy is less commonly given. 
Therefore it is common practice to perform lymph node excisions in patients with CTCL 
and peripheral enlarged lymph nodes. In our study seven patients initially had or later 
developed enlarged palpable axillary or inguinal lymph nodes. SS-R scintigraphy was 
positive in all four of these seven patients with malignant lymph node infiltration. All 
infiltrated lymph nodes were visualized by SS-R scintigraphy. The lymph node areas 
were negative on SS-R scintigraphy in the three patients with dermatopathic 
lymphadenopathy. CT does not allow differentiation between enlarged peripheral lymph 
nodes with histologic evidence of CTCL and nodes demonstrating dermatopathic 
lymphadenopathy. Although our series of patients is small, the results would suggest that 
in contrast to other imaging modalities SS-R scintigraphy may differentiate between 
malignant lymph node infiltration and dermatopathic lymphadenopathy in patients with 
CTCL. In patients with enlarged lymph nodes, a surgical lymph node excision might 
perhaps be avoided on the basis of SS-R scintigraphy results. 
Another possible advantage of SS-R scintigraphy is that the whole body is imaged, so 
that localizations not under clinical suspicion can be evaluated. In tvvo patients, 
previously unsuspected lymphoma localizations were revealed by SS-R scintigraphy, that 
is, in the mediastinum and multiple joints. Although in patient 7 only reactive T 
lymphocytes were seen in the synovial specimen, clonality of these T lymphocytes was 
demonstrated by T -cell receptor gene rearrangement analysis. By analogy with the 
demonstration of clonal T -cell lymphocytic infiltration in dermatopathic 
lymphadenopathy (29,30), the presence of clonal T lymphocytes alone in the synovia, 
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although not sufficient for the diagnosis of malignant infiltration with CTCL. is highly 
suggestive of the (pre)malignant character of the infiltrate. 
On the other hand, SS-R scintigraphy failed to detect an adrenal mass and bone marrow 
infiltration. The adrenal mass may riot have been detected by SS-R scintigraphy because 
of the physiologic uptake of the radioligand in the kidueys. This might have interfered 
with the detection of adrenal involvement, despite the use of SPECT. The reason that 
bone marrow infiltration was not revealed by SS-R scintigraphy is unclear. A locally low 
density of receptors and unknown local factors may be involved. 
At first sight. SS-R scintigraphy appears of minor value in the confirmation of early skin 
disease in CTCL. The skin lesions were visualized in only two patients. In both patients 
the skin disease was in the tumor stage. Skin tumors usually develop at later stages. Only 
one of several plaques was detected by SS-R scintigraphy in patient 3. This skin lesion 
was the presenting lesion several years before mycosis fungoides was diagnosed. In the 
other patients no accumulation of radioactivity was seen in the plaques. We can only 
speculate as to the reason SS-R scintigraphy failed to visualize these thin lesions. One 
explanation might be that most of the patients had been treated for long periods with 
topical corticosteroids. Except for patient 3 in whom only one of several lesions was 
visualized by SS-R scintigraphy, none of the three other patients in whom the skin lesions 
were visualized had been treated with topical corticosteroids. The topical administration 
of corticosteroids might have influenced the SS-R expression on the tumor cells. Long-
term exposure of rat pituitary tumor cells to glucocorticoids has been demonstrated to 
result in downregulation of somatostatin binding because of a decrease in the number of 
SS-Rs per cell (32). Dexamethasone treatment reduced the number of SS-Rs 2.5-fold in a 
rat pancreatic carcinoma cell line (33). 
SS-R scintigraphy is not specific for visualizing tissues infiltrated with malignant 
lymphomas. Neuroendocrine tumors, granulomatous diseases, and autoimmune diseases 
may be visualized by SS-R scintigraphy as well (23). However, no false-positive results 
were seen in this study. 
SS-R scintigraphy not only indicates the sites of involvement of a malignant process, but 
it also gives information on the expression of SS-Rs. Modest activity of somatostatin as a 
single agent has been demonstrated by Witzig et al (34) in low-grade NHL and CTCL. 
SS-R scintigraphy was not performed before or after treatment. It is tempting to postulate 
that patients who have tumors that are shown by SS-R scintigraphy will be most likely to 
respond to therapy with somatostatin or to radiotherapy with a somatostatin analog 
coupled to a ~-emitting radionuclide. 
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SS-R scintigraphy appears to provide an independent approach to the evaluation of 
dissemination of CTCL and CBCL. Although further studies are necessary in a larger 
group of patients before definite conclusions can be made, our results suggest that SS-R 
scintigraphy may be able to distinguish dermatopathic lymphadenopathy from malignant 
lymph node infiltration in certain patients with CTCL and be useful in a complete staging 
work-up of patients with cutaneous malignant lymphomas. 
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SS-R SCC"TIGRAPHY IN HODGKIN'S DISEASE 
Abstract 
Somatostatin receptor (SS-R) scintigraphy successfully shows pnmary cancers and 
metastases in patients with a variety of SS-R positive tumors. In vitro studies have shown 
that SS-Rs are present in lymph nodes from patients with Hodgkin's disease (HD). We 
performed a prospective study in 126 newly diagnosed patients with HD and compared 
the results of SS-R scintigraphy with conventional staging procedures, i.e. physical 
examination, computerized tomography (CT) scanning and other imaging techniques. We 
report positive scintigraphy in all patients. The lesion-related sensitivity was 94% and 
varied from 98% for supradiaphragmatic lesions to 67% for infradiaphragrnatic lesions. 
In comparison with CT scanning and ultrasonography, SS-R scintigraphy provided 
superior results for the detection of Hodgkin's localizations above the diaphragm. In the 
intra-abdominal region, the CT scan was more sensitive than the SS-R scan. A false-
positive scan was rarely seen. In stages I and II supradiaphragmatic HD patients, SS-R 
scintigraphy detected more advanced disease in 18% (15 out of 83) of patients, resulting 
in an upstaging to stage III or IV, thus directly influencing patient management. Our data 
would support the validity of SS-R scanning as a powerful imaging technique for the 
staging of patients with HD. 
Introduction 
Limited stage and disseminated Hodgkin's disease (HD) have different outcomes and 
require different treatment. Patients with limited disease (stages I and II) may be cured 
using regional radiotherapy. However, in approximately 30% of cases, relapses occur (1). 
These patients usually relapse in previously non-irradiated sites (2,3). Therefore. in 
patients with limited disease, prognostic factors are now used to identify patients at high 
risk of relapse if treated with local (radio)therapy alone (3,4). Advanced disease (stages 
III and IV) is treated with systemic chemotherapy (5). HD is nowadays curable in most 
patients (5,6). 
Diagnostic radiology is one of the cornerstones for assessing the extent of the disease. 
Imaging studies that are commonly used include conventional frontal and lateral chest 
radiographs, computerized tomography (CT) scanning, ultrasonography and magnetic 
resonance imaging (MRI). CT or MRI have definite shortcomings. For instance, they do 
not distinguish inactive disease or scar tissue from viable tumor tissue. Diagnosis of 
possible nodal tumor involvement is typically based on detection of lymph nodes > 1.0 
em in short-axis measurements. However, smaller nodes of less than 1.0 em may also 
harbor malignant lymphoma, while larger lymph nodes may be benign. In HD. about 10% 
of involved nodes are normal in size and will therefore not be detected by CT (7). There 
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is an apparent need for further improvement of current methods as well as for the 
development of new imaging techniques. Nuclear medicine studies may offer valuable 
complementary information. 
Somatostatin (SS) is a peptide hormone existing in two different forms, containing 14 or 
28 amino acids (8,9). SS binds to specific SS receptors (SS-Rs). Five distinct subtypes of 
human SS-Rs have been cloned (hSSTR 1-5), all with high affinity binding 
characteristics for SS-14 and SS-28 (10). A wide variety of human malignancies express 
SS-Rs (11). We previously demonstrated the presence of SS-Rs in lymph nodes with HD 
using in vitro SS-R autoradiography (12,13). The presence ofSS-Rs on malignant cells of 
lymphoid origin allows in vivo visualization of sites of HD. The 111 Indium-labeled SS 
analog DTPA-D-Phe1- octreotide (pentetreotide, OctreoScan) has been conveniently used 
to visualize SS-R bearing tumors (11). We have previously reported on the clinical value 
ofSS-R scintigraphy in an initial study in 56 patients with HD (13). Several other groups 
have investigated the clinical significance ofSS-R scintigraphy in the staging ofHD (14-
20), but these studies were based upon relatively small (less than 15) numbers of patients. 
Here we report the results of a prospectively designed study using SS-R scintigraphy for 
the staging of HD in 126 newly diagnosed patients, in which the value of SS-R 
scintigraphy was compared with the conventional work-up. 
Patients and methods 
Patients 
One hundred and twenty-six consecutive, newly diagnosed and previously untreated 
patients with histologically proven HD were enrolled in a prospective study. The stage of 
the disease according to the Ann Arbor classification (21) was established using 
conventional methods which always included a physical examination, chest radiography 
and CT scanning of chest, abdomen and pelvis, and sometimes also ultrasonography of 
the neck and/or abdomen or a lymphangiography. The diagnosis of bone marrow 
involvement was always verified following cytological and histopathological examination 
of a marrow aspirate and biopsy. CT scanning was performed with contiguous I 0 mm 
axial sections after oral and intravenous administration of contrast materiaL All patients 
had given informed consent to the study, which had been approved by the ethics 
committee of the University Hospital Rotterdam. 
On the basis of clinical prognostic factors, two subgroups of patients with 
supradiaphragmatic HD were identified consisting of patients with a favorable and an 
unfavorable prognosis [according to criteria of the European Organization for Research 
and Treatment of Cancer (EORTC) lymphoma collaborative group (3)]. Patients were 
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classified as unfavorable if they were either aged ;o, 50 years or had an erythrocyte 
sedimentation rate (ESR) ;o, 30 mm (with B symptoms: weight loss, fever, night sweats), 
an ESR ;o, 50 mm (with absence of B symptoms), four or more different nodal areas 
involved or a mediastinum/thorax ratio ?:: 0.35. All other patients were considered 
favorable_ 
SS-R scintigraphy 
The maximum interval between conventional staging procedures and SS-R scintigraphy 
was 3 weeks. All examinations were completed before initiation of therapy. 
Patients were injected intravenously with 220 MBq 111 Indium-labeled pentetreotide 
(OctreoScan, Mallinckrodt Medical BV, Petten, The Netherlands)_ Planar total body 
scintigraphy was performed 24 h after injection with a large-field-of-view gamma camera 
(Counterbalance 3700 and ROTA II; Siemens Ganunasonics, Erlangen, Germany) 
equipped with a medium-energy collimator. Repeated scintigrams were performed 48 h 
after injection when accumulation of radioactivity in the abdomen was observed on the 
24-h scintigrams. Laxatives were given to reduce the presence of intestinal radioactivity. 
caused by some hepatobiliary clearance of 111 In-pentetreotide. Head and neck images 
were obtained anteriorly and laterally from both sides. The remainder of the body was 
imaged with separate anterior and posterior images of the thora.;;:, upper abdomen 
(including liver/spleen and kidneys), lower abdomen and extremities. The thorax was 
imaged with arms elevated. Preset counts were 300_000 for the head and neck and 
500.000 for the chest and abdomen or a maximum of 15 min. In all patients, Single 
Photon Emission Computed Tomography (SPECT) images of the upper abdomen were 
made 24 h after injection using a triple-head camera (3000XP, Picker, Cleveland, OH, 
USA)_ Reconstruction of the SPECT data was carried out by filtered back projection_ A 
detailed description of the scanning protocol that is used at the University Hospital 
Rotterdam is given in several reviews (11,22-24). In normal individuals, a physiological 
accumulation of radioactivity is seen at 24h after injection of 111 In-pentetreotide in the 
pituitary and thyroid gland_ the liver_ spleen, kidneys, the intestines, the urinary bladder 
and the gallbladder. Accumulation of radioactivity at other sites is considered to be 
abnormal and indicates the presence of pathological SS-R positive tissue. In organs with 
physiological uptake of 111 In-pentetreotide (e.g. liver and spleen)_ inhomogeneous or 
focal uptake patterns were considered to be indicative of lymphoma. Two experienced 
nuclear medicine physicians evaluated the scans at the same time; they did not know the 
identity of the patients or the results of the conventional staging procedures. If initial 
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interpretations were different (this occurred in less than 5% of cases), a blind discussion 
was held until consensus was reached. 
Assessment of the tnte state of a lesion or a region 
CT scans and other radiological test were evaluated by experienced radiologists without 
knowledge of SS-R scintigraphy data. Lymph nodes of more than 15 mm in diameter 
were considered unequivocally abnormal on CT scanning or ultrasonography and were 
interpreted to represent HD (25). Lymph nodes of less than 10 mm were considered 
benign. Lymph nodes with a diameter between 10 mm and 15 mm were considered 
equivocal. CT and ultrasound criteria for involvement in normal-sized spleen or liver 
included unexplained infiltrates or focal abnormalities of decreased attenuation. The 
spleen was considered enlarged on the CT scan, ultrasonography or SS-R scan if the 
longitudinal diameter was greater than 130 mm (26,27). 
Findings of SS-R scintigraphy were compared with the sum of conventional staging 
procedures. The following lymph node regions were evaluated: occipital left/right upper 
cervical left/right, medial cervical left/right, supraclavicular left/right, submandibular 
left/right, preauricular left/right, axillary left/right, infraclavicular left/right, brachial 
left/right, mediastinal, lung-hilar left/right. para-aortic (including celiac nodes and nodes 
from the hepatic and splenic hili), iliac left/right, inguinal left/right, femoral left/right, 
popliteal left/right, mesenteric and the Waldeyers ring. In addition, all possible 
extranodal sites of involvement were also evaluated. This resulted in a total of 70 
possibly involved lymph node regions and extranodal sites. In case of discrepant findings 
between SS-R scintigraphy and conventional staging procedures, we attempted to 
determine the status of the lesion. Discrepant findings were verified if possible by biopsy 
or by using non-invasive methods, including ultrasonography, MRl, CT or bone 
scintigraphy. All patients were followed during and after therapy. For any documented 
lesion, a final assessment was made of its true state as benign, malignant, or 
indeterminate. This assessment was based on the result of pathological examination 
(histology and/or cytology if done), supplemented by the clinical course. A lesion was 
considered benign because of pathological evidence or if the size was less than 10 mm in 
long-a."<is measurements and the lesion did not increase in size. A lesion was considered 
malignant because of pathological evidence or if the size was more than 15 mm in largest 
diameter or, in retrospect, on the basis of the clinical course (disappearance or change in 
size of a lesion following therapy). The status of the lesion was considered indeterminate 
if the nature of the lesion could not be assessed from the data. Regions without lesions on 
any test were considered to have a true state of absence of disease. Spleen and liver 
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involvement was diagnosed according to the Cotswolds criteria (25). The spleen was 
considered positive for HD if there was unequivocal palpable splenomegaly alone or 
equivocal palpable splenomegaly with radiological confirmation of either enlargement or 
multiple focal defects that were not cystic or vascular. Liver involvement was diagnosed 
if there were multiple focal defects, which were not cystic or vascular, noted with at least 
two imaging techniques. 
Assessment of sensitivity and specificity· of a test 
The sensitivity and specificities of the different tests were calculated separately for each 
of the regions for which the test was performed. For the calculation of the sensitivity. the 
lesions with the true state 'malignant' were used, while for the calculation of the 
specificity the regions without any lesions or only lesions with final assessment 'benign· 
were used. The sensitivity of a test for a lymph node region or extranodal site was defined 
as the number of lesions with a positive test result for that region divided by the total 
number of lesions with final assessment 'malignant' in that region. The specificity of a 
test for a lymph node region or extranodal site was defined as the number of patients with 
a negative test result divided by the total number of patients tested with true state 
'benign/absent' in that region. 
Results 
Patients 
The clinical characteristics of the 126 patients enrolled in the study are shown in Table l. 
Nodular sclerosis and mixed cellularity subtypes were most frequent A majority (70%) 
of the patients had limited HD (stage I or stage II). Table 2 presents the anatomical 
distribution of involved sites of HD. Almost all patients (97%) presented with 
supradiaphragmatical lesions. These were predominantly located in the neck and/or 
mediastinum. Lesions below the diaphragm were apparent in 29% of patients and 
extranodal lesions were rare. 
Sensitivity and specificity of SS-R scintigraph_v 
All 126 patients were positive on SS-R scintigraphy. In these patients, 483 malignant 
lesions, i.e. lesions with involvement of HD, were documented using physical 
examination in combination with SS-R scintigraphy, other imaging techniques, 
histopathology and subsequent follow-up. Of these. 423 lesions were above the 
diaphragm, 54 lesions were below the diaphragm and an additional six lesions were 
recorded. The majority of the lesions were nodal (n = 457). Only 26 were extranodaL 
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Table 1. Clinical characteristics of 126 patients with Hodgkin~s disease 
Age (years) 
Median 
Range 
Sex 
Male 
Female 
Histologic subtype 
Lymphocyte predominance 
~odular sclerosis 
Mixed cellularity 
Lymphocyte depleted 
Not classifiable 
Ann Arbor clinical stage* 
Stage I 
Stage II 
Stage III 
Stage IV 
*based on the results of the standard staging procedures. 
29 
15-75 
75 (59%) 
51 (41%) 
9 (7%) 
95 (76%) 
18 (14%) 
1 (1%) 
3 (2%) 
29 (23%) 
59 (47%) 
25 (20%) 
13 (10%) 
Table 2. Anatomical distribution of the 483 malignant lesions in 126 patients with 
Hodgkin's disease, diagnosed on the basis of standard staging procedures and SS-R 
scintigraphy 
Localization malignant lesion 
Supraclavicular lymph nodes 
Mediastinal lymph nodes 
Cervical lymph nodes* 
Lung hilar lymph nodes 
Axillary lymph nodes 
Infraclavicular lymph nodes 
Para-aortic lymph nodes 
Spleen 
Inguinal lymph nodes 
Iliac lymph nodes 
Lungs 
Bones 
Mesenteric lymph nodes 
Waldeyer's ring 
*occipitaL submandibular and cervical lymph nodes. 
%Patients 
75 
71 
42 
25 
24 
21 
19 
11 
8 
6 
5 
2 
Table 3 gives the sensitivity of SS-R scintigraphy for the detection of HD in each of the 
lymph node regions and extranodal sites. SS-R scintigraphy showed a very high 
so 
Table 3, Sensitivity of various diagnostic approaches for the detection of Hodgkin's disease in the different lymph node regions and 
extranodal sites 
- .... ,_ -~-" 
Localization of malignant lesion Number Physical X-thorax CT scan LAG Ultrasonography SS-R scan 
of lesions examination (%) (%) (%) (%) (%) 
(%) 
~--
Supraclavicular lymph nodes 116 86(115) 80 (15) 96 (45) 100 
Cervical lymph nodes* 91 86 92 (12) 97 (31) 97 
Mcdiastinallymph nodes 90 61 (82) 96 100 
Lung hilar lymph nodes 45 54 (39) 91 96 
Axillary lymph nodes 38 58 77 (35) 95 
Infraclavicular lymph nodes 36 78 100 
Ch 
"' Lungs 6 50 83 83 ,
Ch 
0 
Para-aortic lymph nodes 24 88 75 (4) 100 (7) 50 z 
::l 
0 
Spleen 14 50 93 100 (9) 93 ~ 
" 
Iliac lymph nodes 
~ 
8 88 100(1) 38 
"' 
:r: 
Inguinal lymph nodes 7 71 71 100 0 0 
0 
Total 483 94 ~ 
'" 0 
*occipital, submandibular and cervical lymph nodes; I ,AG, bipedal lymphnngiography. Numbers in parentheses indicate frequcney at which the test was pcrfonncd, only Ul 
'" 00 given if different from the number of malignant lesions. )> Ch 
"' 
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sensitivity (95%-100%) for the detection of HD in the neck, mediastinum, lung hila and 
axillae (Figure 1 ). 
Figure l 
SS-R scintigraphy in a 63-ycar-old woman 
with a 2-month history of cervical lymph 
node enlargement that biopsy revealed to be 
Hodgkin's disease. Planar anterior image of 
the neck and upper thorax at 24 h after 
injection of 111 In-pcntctrcotidc. There is 
marked uptake of '; 1ln-pcntctrcotidc in 
lymph nodes in the right cervical and 
supraclavicular region (arrows). 
Physiological accumulation of radioactivity 
is seen in the thyroid (T). liver (L) and 
spleen (S). 
Of the six malignant intrapulmonallesions, five were visualized using SS-R scintigraphy. 
The smallest lesion above the diaphragm detected using SS-R scintigraphy had a diameter 
of 5 mm and was located in the supraclavicular region. Below the diaphragm the 
sensitivity of SS-R scintigraphy ranged from 38%-100% (Figure 2). The scintigraphic 
sensitivity for para-aortic lesions was low, i.e. 50%. In four patients the para-aortic 
lesions were visualized only on SPECT but were not shown on the planar images. There 
was no apparent relationship between the size of the pathologic lymph node and the 
probability of a positive para-aortic SS-R scan. The smallest maliguant lesion under the 
diaphragm that was detected by SS-R scintigraphy was an inguinal lymph node with a 
diameter of 15 mm. In six patients there was pathologic evidence of bone marrow 
infiltration with HD. In only one of these patients did the SS-R scan revealed marrow 
positivity. 
The sensitivity of SS-R scintigraphy for the detection of supradiaphragmatic lesions was 
98% and for lesions below the diaphragm 67%. For nodal lesions the sensitivity was 94% 
and for extranodallesions 88%. The sensitivity for all lesions combined was 94%. 
In four lesions, SS-R scintigraphy gave a false-positive result. In two patients, non-
specific accumulation of radioactivity was seen in the pleural region, probably as a result 
of old aspecific lesions. In the third patient, a large hematoma in the anterior iliac spine 
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Figure 2 
Visualization of abdominal Hodgkin's 
disease in a 39-year-old man using SS-R 
scintigraphy. Planar anterior image of the 
lower abdominal region scanned at 24 h. The 
SS-R scan reveals positive para-aortic (upper 
arrows) and right inguinal lymph nodes 
(lower arrow). There is physiological 
accumulation of radioactivity in the kidneys 
(K). 
after a bone marrow biopsy caused aspecific accumulation of radioactivity at that site. 
The fourth patient with a false-positive SS-R scan showed uptake in the shoulder, owing 
to a bursitis. Thus, the specificity ofSS-R scintigraphy is high. 
Sensitivity of different imaging techniques 
Table 3 gives the estimated sensitivities of each of the imaging techniques used in this 
study. expressed per distinct lymph node region and extranodal site. In comparison with 
conventional imaging modalities, SS-R scintigraphy has a high sensitivity for the 
detection oflymph nodes in the neck, axilla and groin. SS -R scintigraphy is also superior 
for the visualization of mediastinal localizations ofHD. However. in the intra -abdominal 
region. the SS-R scintigraphy is inferior to the CT scan and ultrasonography. 
Comparison of SS-R scintigraphy with conventional staging procedures 
In Table 4 an overview is given of a comparison between the results ofSS -R scintigraphy 
and the conventional staging procedures in the 126 patients. In 43% (n = 54) of the 
patients, SS-R scintigraphy disclosed activity suggestive of HD that had not be en 
revealed following conventional staging procedures. In 24 of these 54 patients, the 
enhanced diagnostic yield of SS -R scintigraphy could be confirmed by additional 
investigations, i.e. by repeated palpation (n = 3), subsequent additional radiodiagnosis (n 
= 14), cytopathology (n = 2) and/or the clinical course (n = 5). We were unable to verify 
30 discrepant SS-R scintigraphy and conventional staging findings because of ethical 
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Table 4. Comparison of the results of SS-R scintigraphy with the conventional staging 
procedures in 126 patients with Hodgkin's disease 
Patients 
Result Number % 
SS-R scan detects new lesions 54 43 
SS-R scan misses lesions 14 11 
SS-R scan detects new lesions, but also 8 6 
misses lesions in the same patient 
Agreement between SS-R scan and 50 40 
conventional staging procedures 
considerations, lack of patient consent or lack of therapeutic consequences. In 14 patients 
(11 %), lesions apparent by conventional staging were missed on SS -R scintigraphy. In 
eight patients, the result of SS-R scintigraphy was mixed, i,e, in the same individual 
additional lesions were disclosed by SS-R scintigraphy, but other lesions were missed, In 
40% of patients, the results of SS-R scintigraphy and conventional staging procedures 
were concordant. 
Table 5 shows the estimated clinical stages based on the sum of the conventional staging 
procedures compared with the clinical stages based on the results of SS-R scintigraphy 
only, 
Table 5. Comparison of the clinical stage based on the results of the SS-R scan with the 
clinical sta~e based on conventional work-up 
*indicate a change in clinical stage with potential consequences for the treatment choice. 
The additional lesions revealed using SS-R scintigraphy upgraded the clinical stage in 28 
patients, As a result, the treatment plan would have changed in 18 patients (14%), 
However, in those nine patients (7%) in whom SS-R scintigraphy had failed to recognize 
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certain apparent localizations of HD) the clinical stage. if based on SS-R scintigraphy 
only, would have been underestimated. 
Ana(vsis of SS-R scintigraphy in favorable and unfavorable subjects of stage I and II 
patients 
Stages I and II patients with HD are commonly stratified by risk (according to selected 
clinical favorable or unfavorable prognostic factors) to adjust and select more or less 
intensive therapy, We considered in more detail the consequences of the results of the SS-
R scan in these prognostically distinct subsets among all 88 patients with stage I and 
stage II HD. Three different subgroups were identified: favorable supradiaphragmatic HD 
(37 patients), unfavorable supradiaphragmatic HD (46 patients) and infradiaphragmatic 
HD (five patients)- Table 6 shows the localization of the additional new lesions found 
using SS-R scintigraphy for each of the three prognostic subgroups of stages I and II 
patients. 
Table 6. Additional lesions demonstrated with SS-R scintigraphy in 88 stages I and II 
Hodgkin's disease patients subdivided according to risk 
Number of patients(%) with additional lesions 
Nodal Extranodal * 
Patient prognosis category Above Below Above and 
diaphragm diaphragm below 
diaphragm 
Favorable patients (n = 37) 13 (35) 4 (ll) I (3) 2 (5) 
Unfavorable patients (n = 46) 10 (22) 3 (7) 3 (7) 2 (4) 
Abdominal HD (n ~ 5) 3 (60) 0 0 0 
*if the SS-R scan detected additional nodal lesions as well as extranodal sites in the same patient the patient 
was scored as cxtranodal. 
In 19% (7 out of 37) of the favorable patients and in 17% (8 out of 46) of the unfavorable 
patients SS-R scintigraphy disclosed previously unknown lesions below the diaphragm or 
at extranodal sites. resulting in an upstaging to stage III or stage IV. In three of the five 
patients with infradiaphragmatic HD, the disease was upstaged to stage III as a 
consequence ofSS-R scintigraphy demonstrating previously undetected lesions above the 
diaphragm. 
Discussion 
Studies concerning the value of staging laparotomy have demonstrated that about 30% of 
patients with stage I and stage II HD have occult splenic or upper abdominal nodal 
involvement not detected by CT, MRI or lymphangiography (28,29), An indirect 
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estimation of the probability of occult abdominal disease will direct treatment choice in 
patients with limited stage HD. In patients with supradiaphragmatic HD, clinical 
prognostic factors are used as surrogate markers for more or less extended disease to 
select a more or less intensive treatment approach (3,30). Patients with favorable 
prognostic factors are usually candidates for radiation therapy with or without dose-
reduced chemotherapy. Patients with unfavorable prognostic factors receive more dose-
intensive chemotherapy with or without radiation therapy as the initial treatment. 
However, more sensitive imaging techniques, which would directly demonstrate 
abdominal involvement of HD more precisely, would allow for better tailoring of 
treatment. 
The expression of SS-Rs on cells in lymph nodes from patients with HD, as demonstrated 
several years ago (12,13), has opened possibilities for in vivo visualization of SS-R 
positive Hodgkin's localizations. Several groups have shown the feasibility of SS-R 
scintigraphy for imaging of HD (13-20). However, the numbers of patients in these 
studies have remained minimal, varying from two to 11 patients, so that the clinical value 
of SS-R scintigraphy for staging of HD has never been properly established. Our prior 
experience in 56 HD patients yielded a high patient-related sensitivity (13). This 
prospective study was designed to investigate the role of SS-R scintigraphy in the initial 
staging of 126 patients with untreated HD. The results of the study confirm 
unambiguously that SS-R scintigraphy has a notably high positivity in patients with HD. 
In our study. each patient had one or more Hodgkin's localizations that were positive on 
the SS-R scan, demonstrating that Hodgkin's lymphomas. without exception, express 
SS-Rs. 
The results of our study would support the validity of SS-R scanning as a powerful 
diagnostic method for staging patients with HD. The lesion-related sensitivity was 94% 
and varied from 98% for supradiaphragmatic lesions to 67% for infradiaphragmatic 
lesions. In contrast to most other studies, in which new patients and previously treated 
patients were evaluated together, our study specifically addressed the question of the 
value of SS-R scintigraphy in newly diagnosed cases ( 14, 16,20). 
Compared with CT scanning and ultrasonography, SS-R scintigraphy provided superior 
results for the detection of Hodgkin's localizations above the diaphragm. Malignant 
lymph nodes as small as 5 mm diameter were visualized. In the intra-abdominal region, 
the CT scan appeared considerably more sensitive than SS-R scintigraphy. The limited 
sensitivity for intra-abdominal Hodgkin's lesions is a disadvantage of SS-R scintigraphy. 
Optimal visualization of the para-aortic and iliac regions is hampered by the 
physiological accumulation of the labeled pentetreotide in the liver and spleen and its 
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elimination by bile, bowel and kidneys. Apparently. the use of SPECT can overcome this 
problem at least in part. We have used standard filtered back projection for the 
reconstruction of the SPECT data (31 ). A drawback of this method is the presence of 
considerable reconstruction artifacts in the region betvveen the liver, spleen and kidneys. 
It is conceivable that the use of iterative reconstruction methods will avoid such artifacts. 
Additionally, the extension ofSPECT imaging to the lower abdominal region may further 
improve the sensitivity. The sensitivity of SS-R scintigraphy in the intra-abdominal 
region is currently insufficient to recommend its use in all patients. However, in stage I 
and stage II patients, SS-R scintigraphy has added value in detecting more advanced 
disease in a significant proportion of the patients, thus directly impacting on treatment 
decision. Not only patients with unfavorable prognostic factors but also patients with 
favorable prognostic factors appear to carry more disseminated disease according to in 
vivo SS-R evaluation. We recognize that lack of histological proof of our imaging 
interpretations is a significant deficiency of our study. However, invasive diagnostic 
procedures represent increased risk for the patient and staging laparotomies are now 
infrequently performed. Because there were only a small fraction of false-positive SS-R 
scintigraphy findings (four lesions). we think that most of the unresolved SS-R 
scintigraphy findings are probably true positive. 
The usefulness of SS-R scintigraphy is heavily dependent on optimal equipment and 
technique. We administered a high dose of 111Indium (always > 200 MBq). which 
probably enhances the sensitivity of detection. Furthermore, the counting time of images 
should be sufficiently long in order to avoid lesions with a relatively low uptake of 
radioactivity being missed. In our experience, SPECT imaging of the upper abdomen is 
essentiaL In a considerable nmnber of patients (four out of 24) with abdominal HD. the 
para-aortic lesions were not detected on the planar images but were visualized by SPECT. 
This makes the procedure time-consuming (SPECT, counting time) and expensive (dose, 
time). However, in our study, the addition of an SS-R scan to the work-up in patients witl1 
stages I and II HD proved to be cost-effective. The results of the cost-effective study will 
be reported in a separate paper. 
SS-R scintigraphy by its nature can never compete with conventional imaging in 
anatomical delineation of the disease sites, but the technique offers complementary 
information owing to its physiological features. In patients with HD, the presence and 
abundance of SS-R expression can easily be detected in vivo. At present, peptide 
receptor-targeted radionuclide therapy (PRRT) is being developed as a new therapeutic 
option for cancer patients. A promising effect of therapy with multiple high 
radiotherapeutical doses of 111In-pentetreotide was demonstrated in patients with end-
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stage neuroendocrine tumors (32). In this study, there was a tendency towards better 
results in patients whose tumors had a higher accumulation of the radioligand. Most 
neuroendocrine tumors bave a higb SSTR-2 expression, while lymphomas generally have 
a medium to low rate of SSTR-2 expression. However, in contrast to the relatively 
radioresistent neuroendocrine tumors, lymphomas are generally radiosensitive. Thus, 
despite the low receptor expression, it is possible to expect therapeutic effects of targeted 
treattnent with 111ln-pentetreotide, or one of its variants, e.g. 90Y-DOTATOC (33), in 
patients with HD. Critical organs for PRRT are the kidneys and probably the bone 
marrow. This imposes a limit to the maximal activity that can be employed safely. 
Whether PRRT is a promising option for malignant lymphoma remains to be 
investigated. 
Gallium scintigraphy is not routinely used for the initial staging of HD, owing to the 
lower sensitivity compared with the CT scan, especially in the abdomen (34-36). 
Traditionally, gallium scintigraphy plays a role in the evaluation of the post-treatment 
residual mass. Gallium imaging may be helpful to confirm the presence of residual active 
disease and resistance to treattnent (37 -40). However, it tends to underestimate small 
deposits of disease (39,41). A number of reports have recently demonstrated a potential 
role for whole-body positron emission tomography with 2-[lSF]-fluoro-2-deoxy-D-
glucose (FDG-PET) in lymphoma imaging (42). Published results indicate that FDG-PET 
may be equal or superior to CT for the detection of nodal as well as extranodal 
involvement in HD (43,44). For post-treattnent evaluation, data indicate that FDG-PET 
has a higher diagnostic and prognostic value than CT (45.46). We are currently 
investigating in a prospective study on the role of SS-R scintigraphy in the management 
of residual masses. Furthermore, it will be of interest to investigate the comparative 
values of gallium scarming, SS-R scintigraphy and FDG-PET in the diagnostic work-up 
of patients with Hodgkin's disease. 
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SS-R SCINTIGRAPHY IN LOW-GRADE NHL 
Abstract 
In this prospective study somatostatin receptor (SS-R) scintigraphy was compared with 
conventional staging procedures for the initial staging of patients with low-grade non-
Hodgkin's lymphoma (NHL). Fifty consecutive untreated patients with low-grade NHL 
undenvent SS-R scintigraphy as part of their initial staging. Planar images were obtained 
24 and 48 h after intravenous injection of220 MBq 111In-pentetreotide. SPECT images of 
the upper abdomen were obtained from all patients. SS-R scans were evaluated blindly 
without knowledge of the results of the conventional staging methods. SS-R scintigraphy 
findings were compared with the results of physical and radiologic examinations. SS-R 
scintigraphy findings were positive in 42 of 50 patients (84%). In 10 patients (20%), the 
SS-R scan revealed new lesions that had not been revealed by conventional staging 
procedures. These 10 patients were all upgraded to a higher stage. Consequently, the 
treatment plan would have been altered in 5 patients (! 0% ). However, in 19 patients 
(38%), lesions apparent after conventional staging methods were missed by SS-R 
scintigraphy. The sensitivity of SS-R scintigraphy varied from 62% for supra-
diaphragmatic lesions to 44% for infradiaphragmatic lesions. The specificity of SS-R 
scintigraphy was high (98%-1 00% ). In comparison with CT scanning and sonography, 
SS-R scintigraphy is inferior for the visualization of NHL lesions in the thorax and 
abdomen. Although SS-R scintigraphy findings are positive in a large proportion of 
patients with low-grade NHL, in most patients only part of the lesions can be visualized. 
Because of the limited sensitivity~ we recommend SS-R scintigraphy for initial staging of 
patients with low-grade NHL only in selected conditions and not for the general work-up. 
Introduction 
Low-grade non-Hodgkin's lymphomas (NHLs) often present as disseminated disease. 
Bone marrow involvement is frequently seen. The survival curves reveal a progressive 
decline with no indication of plateau, providing no evidence of a cure. The median 
survival is about 8 years (! ). Local irradiation can result in prolonged freedom from 
progression and possibly a cure in approximately half of patients with stage I and small-
volume stage II low-grade NHL (2,3). Therefore, for low-grade NHLs, staging is 
important to identifY patients with truly localized disease who may be cured by 
radiotherapy. 
Somatostatin receptors (SS-Rs) are present in a wide variety of human tumors (4). The 
radio labeled SS analog [ 111 Indium-diethylenetriarninepentaacetic acid-D-phenylalanine ]-
octreotide has been used successfully for the in vivo visualization of SS-R positive 
tumors (4). With in vitro autoradiography, SS-R presence was shown in lymph nodes 
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with NHLs. Of II !ow-grade B-ce!l 1'\HLs, I 0 were SS-R positive, and a high receptor 
density was restricted to the neoplastic follicles (5). 
Studies evaluating the clinical impact of SS-R scintigraphy for the staging of NHLs are 
rare, and they are all based on relatively small numbers of patients and heterogeneous 
patient groups (6-13). 
We report the results of a prospective study of 50 patients newly diagnosed with low-
grade NHL in which the value of SS-R scintigraphy was assessed. 
Patients and methods 
Patients 
Fifty consecutive, newly diagnosed and previously untreated patients with low-grade 
NHL were enrolled in a prospective study. The diagnosis of low-grade NHL was 
substantiated by histologic and immunohistologic methods and was classified according 
to the Working Formulation (14). The stage of the disease according to the Ann Arbor 
classification (15) was established by conventional methods that always included a 
physical examination; inspection of the Waldeyer's ring by an ear, nose, and throat 
specialist; chest radiography; computerized tomography (CT) scanning of the chest, 
abdomen. and pelvis; and sometimes sonography of the neck or abdomen. The diagnosis 
of bone marrow involvement was always verified after cytologic, immunologic, and 
histopathologic examination of marrow aspiration and biopsy. CT scanning was 
performed with contiguous 10 mm axial sections after oral and intravenous 
administration of contrast material. All patients gave informed consent to the study, 
which was approved by the ethics committee of the University Hospital Rotterdam. 
SS-R scintigraph)'' 
The ma···.::imum interval between conventional staging procedures and SS-R scintigraphy 
was 3 wk. All examinations were completed before initiation of therapy. Patients were 
injected intravenously with 220 MBq 111ln-pentetreotide (OctreoScan; Mallinckrodt. Inc. 
BV, Petten, The Netherlands). Planar total body scintigraphy was performed 24 h after 
injection with a large-field-of-view gannna camera (Counterbalance 3700 and ROTA !I; 
Siemens Gammasonics, Erlangen, Germany) equipped with a medium-energy collimator. 
Repeated scintigrams were obtained 48 h after injection, when accumulation of 
radioactivity in the abdomen was observed on 24-h scintigrams. Laxatives were given to 
reduce intestinal radioactivity caused by some hepatobiliary clearance of n 1In-
pentetreotide. Head and neck images were obtained anteriorly and laterally from both 
sides. The remainder of the body was imaged with separate anterior and posterior images 
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of the thorax, upper abdomen (including liver/spleen and kidneys), lower abdomen, and 
extremities. The thorax was imaged with arms elevated. Preset counts were 300,000 for 
the head and neck and 500,000 for the thorax and abdomen, or a maximum of 15 min. In 
all patients, SPECT images of the upper abdomen were made 24 h after injection using a 
triple-head camera (3000XP; Picker, Cleveland, OH). SPECT data were reconstructed by 
filtered backprojection. A detailed description ofthe scanning protocol is given in several 
reviews (16-18). In healthy individuals, a physiologic accumulation of radioactivity may 
be seen 24 h after injection of 111 In-pentetreotide in the pituitary gland, thyroid gland, 
liver, spleen, kidneys, intestines, urinary bladder, and, frequently, the gallbladder. 
Accumulation of radioactivity at other sites is considered to be abnormal and indicates 
the presence of pathologic SS-R positive tissue. In organs with physiologic uptake of 
111In-pentetreotide (e.g., liver and spleen) inhomogeneous or focal uptake patterns were 
considered to be indicative of lymphoma. Independent, blinded evaluation of SS-R scans 
was performed by two experienced nuclear medicine physicians at the same time. If the 
initial interpretations were different (occurring in less than 5% of patients), a blind 
discussion was held until consensus was reached. The intensity of pathologic uptake of 
111 In-pentetreotide in the lesions observed on the planar images was graded 
semiquantitively as follows: grade 0 ~ negative, no abnormal activity; grade 1 ~ 
equivocally positive, small amount of accumulation of radioactivity; grade 2 ~ clear 
accumulation of radioactivity, intensity less than that of the liver; and grade 3 = clear 
accumulation of radioactivity, intensity equal to or greater than that ofthe liver. The SS-R 
scan was considered positive in any given patient if at least one of the identified 
lymphoma lesions was positive on the scan (grade 1, 2, or 3). 
Assessment of the true state of lesion or region 
CT scans and other radiologic tests were evaluated by experienced radiologists without 
knowledge of the SS-R scintigraphy data. Lymph nodes > 15 mm in diameter were 
considered unequivocally abnormal on CT scanning or sonography and were interpreted 
to represent NHL. Lymph nodes <10 mm were considered benign. Lymph nodes with a 
diameter of 10-15 mm were considered equivocal. CT and sonography criteria for 
involvement in a normal-sized spleen or liver included unexplained infiltrates or focal 
abnormalities of decreased attenuation. The spleen was considered enlarged on CT, 
sonogram, or SS-R scan if the longitudinal diameter was> 130 mm (19,20). 
Findings of SS-R scintigraphy were compared with the sum of the results of conventional 
staging procedures. The following lymph node regions were evaluated: occipital 
left/right, upper cervical left/right, medial cervical left/right, preauricular left/right, 
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submandibular left/right, supraclavicular left/right, infraclavicular left/right, axillary 
left/right, brachial left/right, mediastinal, lung-hilar left/right, para-aortic (including celiac 
nodes and nodes from the hepatic and splenic hili), iliac left/right, inguinal left/right, 
femoral left/right, popliteal left/right, mesenteric, and the Waldeyer's ring. In addition, all 
extranodal sites of potential involvement were also evaluated. This process resulted in a 
total of 70 possibly involved lymph node regions and extranodal sites. In cases of 
disagreement betv.;een findings in SS-R scintigraphy and conventional staging 
procedures, we attempted to determine the status of the lesion. Status was verified if 
possible by biopsy or using noninvasive methods, including sonography, magnetic 
resonance imaging, CT or bone scintigraphy. All patients were followed during and after 
therapy. For any documented lesion, a final assessment was made of its true state as 
benign, malignant, or indeterminate. This assessment was based on the result of the 
pathologic examination (histology or cytology if done) supplemented by the clinical 
course. A lesion was considered benign because of pathologic evidence, or if the long-
axis measurement was <1 0 mm and the lesion did not increase in size. A lesion was 
considered malignant because of pathologic evidence, or if the largest diameter was > 15 
mm, or in retrospect on the basis of the clinical course (disappearance or change in size of 
a lesion of>lO mm after therapy). The status of the lesion was considered indeterminate 
if the nature of the lesion could not be assessed from the data. Regions without lesions on 
any test were considered to have a true state of absence of disease. The spleen was 
considered positive for NHL if there was unequivocal palpable splenomegaly alone or 
equivocal palpable splenomegaly with radiologic confirmation of either enlargement or 
multiple focal defects that were neither cystic nor vascular. Liver involvement was 
diagnosed if there were multiple focal defects that were neither cystic nor vascular, noted 
with at least tvvo imaging techniques. 
Assessment of sensitivity and specificity of a test 
The sensitivity and specificity of the different tests were calculated separately for each of 
the regions for which each test was performed. For the calculation of sensitivity, the 
lesions with a true state of malignancy were used, whereas for the calculation of 
specificity, the regions with no lesions or only lesions with a final assessment of benign 
were used. The sensitivity of a test for a lymph node region or extranodal site was defined 
as the number of lesions with a positive test result for that region divided by the total 
number of lesions with a final assessment of malignant in that region. The specificity of a 
test for a lymph node region or extranodal site was defined as the number of patients with 
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a negative test result divided by the total number of patients tested with true state of 
benign/absent in that region. 
Results 
Patients 
The clinical characteristics of the 50 patients with low-grade NHL enrolled in the study 
are listed in Table 1. 
Table 1. Clinical characteristics of 50 patients with low-grade ~HL 
Characteristic No. of patients(%)":-
Sex 
Male 
Female 
Ann Arbor clinical stage* 
Stage I 
Stage II 
Stage III 
Stage IV 
Histologic subtype (Working Formulation) 
A: Small lymphocytic 
B: Follicular. predominantly small cleaved cell 
C: Follicular. mixed small cleaved and large cell 
MALT 
'Cnclassifiable low-grade 
30 (60) 
20 (40) 
25 (50) 
5 (!0) 
7 (!4) 
!3 (26) 
7 (\4) 
2 (4) 
30 (60) 
9 (!8) 
2 (4) 
*based on re:mlts of standard staging procedures;~ Age range, 28-76 y; mean age. 51 y. 
Follicular lytmphoma constituted for 64% of the histologies. There were 9 patients (18%) 
with a lymphoma of mucosal-associated lytmphoid tissue (MALT). lmmunopheno-
typically, all NHLs were ofB-cell origin. Localized disease (i.e., stages I or II) was more 
common ( 60%) than advanced disease ( 40% ). Details of the anatomic distribution of the 
malignant lesions are given in Table 2. Lymph nodes in the neck were involved in 56% of 
the patients. Approximately half of the patients (52%) presented with infradiaphragmatic 
disease. Below the diaphragm, the para-aortic region and the mesenteric and inguinal 
lymph nodes were most frequently involved. The most common sites of extranodal 
involvement were the stomach and orbital eye. Bone marrow infiltration with NHL was 
apparent in 22% of patients. 
Patient-related sensitivity ofSS-R scintigraph): 
The SS-R scan was positive in 42 of 50 patients (84%). An entirely negative scan was 
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Table 2. Anatomic distribution of 162 malignant lesions in 50 patients with low-grade 
NHL* 
Localization malignant lesion % of patients 
Neck lymph nodes 56 
Para-aortic lymph nodes 34 
Mesenteric lymph nodes 22 
Inguinal lymph nodes 20 
Mediastinal lymph nodes 18 
Axillary lymph nodes 18 
Iliac lymph nodes 12 
Spleen 10 
Stomach 10 
Orbit/eye 10 
Lung hilar lymph nodes 4 
W aid eyer's ring 4 
Intestine 4 
Skin 4 
Central nervous system 2 
Urinary bladder 2 
Pleura 2 
Parotid gland 2 
Mouth 2 
*diagnosed on basis of conventional staging procedures and SS-R scintigraphy. 
seen in 8 of 50 patients (16%). In 4 of9 patients (44%) with a MALT lymphoma, the SS-
R scan was negative; 2 had gastric lymphoma and 2 had ocular lymphoma. The SS -R 
scans in the other 5 patients with MALT lymphoma were positive; 2 had lymphoma of 
the stomach, l had lymphoma of the parotid gland, l had lymphoma of the orbit, and l 
had lymphoma ofthe orbit, stomach, intestine, spleen and abdominal lymph nodes. 
Comparison of SS-R scintigraphy with conventional staging procedures 
Table 3 compares the results of SS-R scintigraphy with those of conventional staging 
(exclusive bone marrow examination) in the 50 patients. In I 0 patients (20% ). the SS -R 
scan revealed new lesions suggestive of NHL that were not revealed by conventional 
staging procedures. We were unable to verify the discrepant findings in these 10 patients 
because of ethical considerations, lack of patient consent, or lack of therapeutic 
consequences. In 19 patients (38%), lesions apparent after conventional staging were 
missed on SS-R scintigraphy. Furthermore, in 3 patients (6%). the results of the 
comparison were mixed; that is, in the same patient, new lesions were disclosed by SS -R 
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Table 3. Comparison of results of SS-R scintigraphy with those of conventional staging in 
50 patients with low ...grade NHL 
Patients 
Result Number % 
SS-R scan detects new lesions 10 20 
SS-R scan misses lesions 19 38 
SS-R scan detects new lesions and 3 6 
misses lesions in same patient 
Agreement between SS-R scan and 18 36 
conventional staging procedures 
scintigraphy and other lesions were missed. Finally, the results of SS-R scintigraphy and 
conventional staging procedures were concordant in 36% of the patients. 
Table 4 shows the clinical stage based on conventional staging procedures (excluding the 
bone marrow evaluation) in comparison with the clinical stage based on conventional 
staging procedures complemented with SS-R scintigraphy. 
Table 4. Clinical stage based on conventional staging procedures complemented with SS-R 
scintigraphy compared with clinical stage based on conventional staging only 
Stage based on 
conventional staging 
complemented with 
SS-R scintigraphy 
II 
Ill 
IV 
Total 
15 
5 
4" 
I<· 
25 
Stage based on conventional staging only* 
II 
4 
0 
0 
5 
Ill 
0 
0 
7 
0 
7 
IV 
0 
0 
0 
13 
13 
Total 
16 
9 
II 
14 
50 
* conventional staging procedures excluding bone marrow pathology; tchange in clinical stage with potential 
consequences for treatment choice. 
Because of the different SS-R scintigraphy findings, the clinical stage was upgraded in 10 
patients (20%). As a result, the treatment plan would have been altered in 5 patients 
(!0%). On the other hand, in 12 patients (24%), in whom SS-R scintigraphy missed 
certain apparent localizations ofNHL, the clinical stage would have been underestimated 
when based only on the results of SS-R scintigraphy. 
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Lesion- related sensitivity and specificity ofSS-R scintigraphJ' 
In the 50 patients, a total of 162 malignant lesions were distinguished from the physical 
examination in combination with SS-R scintigraphy, other imaging techniques, 
histopathology, and the outcome of subsequent follow-up. Of these, 95 lesions were 
localized above the diaphragm, 64 lesions were below the diaphragm, and 3 were 
elsewhere. A minority of the lesions were extranodal (n = 20). Table 5 gives the 
sensitivity of SS-R scintigraphy for detecting lymphoma in each of the lymph node 
regions and extranodal sites. For supradiaphragmatic nodal lesions, the sensitivity varied 
from 59% to 78% (Figure I). 
Figure 1 
Visualization of submandibular lymph node 
in 42-y-old woman with stage lA XHL of 
low-grade malignancy by SS-R scintigraphy. 
Right lateral image of head and neck shows 
grade 2 pathologic uptake (arrow) within 
submandibular lesion. Normal uptake of 
radioactivity is seen in thyroid. On physical 
examination, a lymph node of 3 em in 
diameter was palpated. 
The sensitivity was best for lesions in the mediastinum (78%). The smallest NHL lesion 
above the diaphragm that was correctly visualized by SS-R scintigraphy was located in 
the upper cervical region and had a diameter of I .2 em. The largest supradiaphragmatic 
lesion that was missed by SS-R scintigraphy had a diameter of 4.0 em and was located in 
the axilla. The scintigraphic sensitivity for lymph nodes in the abdominal and inguinal 
regions varied from 30% to 54% (Figures 2 and 3). Only 38% of the gastrointestinal 
lymphomas were visualized by SS-R scintigraphy. In the para-aortic and iliac regions, 
small lymph nodes of 1.5 em in diameter were detected by SS-R scintigraphy. However. 
I mesenteric lymph node mass of 7.0 em in diameter was entirely missed by SS-R 
scintigraphy. In I patient, lymphoma localization in the stomach was detected by SPECT 
only, whereas it had not been visualized on the planar images. In the other patients, 
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Table 5. Sensitivity of various diagnostic approaches for detection of low-grade NHL lesions in different lymph node regions and cxtranodnl 
Localization of malignant lesion Number of Physical Chest CT scan LAG Sonography SS-R scan 
malignant examination radiograph (%) (%) (%) (%) 
lesions (%) (%) 
Cervical lymph nodes* 38 96 70 (10) 66 
Supraclavicular lymph nodes 17 90 63 (8) 59 
Axillmy lymph nodes 16 94 86 (14) 63 
Mediastinal lymph nodes 9 25 (8) 100 (8) 78 
Orbit/eye 6 67 40 (5) 33 
Lung~hilar lymph nodes 3 0 100 67 
Pnra-aortic lymph nodes 17 82 100 (2) 43 (7) 35 
"' w 
"' lvlescnteric lymph nodes II 100 67 (6) 36 'n z 
Inguinal lymph nodes 13 69 85(13) 54 ::l Cl 
s: 
Iliac lymph nodes 10 90 30 "' 0:
-< 
Stomach/intestine 8 13 38 
z 
'""' 
0 
Spleen 5 100 100 100 (2) 100 6 
s: 
* occipital, submandibular and eerYieallymph nodes; LAG, bipedallymphangiogmphy. Numbers in parentheses indicate frequency at which the test was performed and t:J tn 
-
are giYen only if different from number of malignant lesions. z 0 0: 
"' '""' 
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Figure 2 
SS-R scintigraphy in 36-y-old man with 
low-grade ~HL shows multiple enlarged 
lymph nodes of 2-3 em in diameter in right 
inguinal and iliac regions. Pathologic lymph 
nodes arc clearly seen (grade 2 uptake, 
arrow). )\annal accumulation of 
radioactivity is seen in bladder and kidneys. 
Figure 3 
SS-R scintigraphy in 52-y-old woman with 
low-grade ;\HL shows pathologic uptake in 
abdominal region bctvvecn kidneys (arrow). 
Normal uptake of radioactivity is seen in 
enlarged spleen. Normal uptake is also seen 
in liver and kidneys. CT scan of abdomen 
showed enlarged mesenteric lymph nodes. 
SPECT provided no added value. In only I of the patients (9%) with bone marrow 
infiltration, the SS-R scan revealed marrow positivity. The sensitivity of SS-R 
scintigraphy for all lesions combined was 55%, varying from 62% for 
supradiaphragmatic lesions to 44% for lesions below the diaphragm. For nodal lesions, 
the sensitivity was 56%, and for extranodal sites, it was 45%. The estimated overall 
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sensitivity of SS-R scintigraphy in the 42 patients with a positive scan was 60%. The 
specificity of SS-R scintigraphy was high (98%-1 00%). The intensity of uptake of 111 In-
pentetreotide in the malignant lesions was negative in 45%, grade 1 in 31%, grade 2 in 
23%, and grade 3 in 1%. The maximum uptake of 111In-pentetreotide in the malignant 
lesions per patient was negative in 16%, grade 1 in 28%, grade 2 in 54%, and grade 3 in 
2%. The mean uptake per patient was grade 1.07. 
In six lesions, a false-positive result was obtained. In three patients, nonspecific 
accumulation of radioactivity was caused by recent surgery. Extreme dental caries caused 
aspecific uptake in the jaws of the fourth patient. The fifth patient suffered from 
autoimmune hemolytic anemia and showed a high uptake of radioactivity in an enlarged 
spleen. After a splenectomy, the histopathologic examination did not provide indications 
of splenic infiltration of NHL. In the last patient, a multinodular goiter caused a high 
aspecific accumulation of radioactivity in the thyroid. Cytologic and immunologic 
analyses of a thyroid puncture were negative for NHL. 
Sensitivity of several imaging techniques 
Table 5 gives the estimated sensitivities of each imaging technique applied, expressed per 
distinct lymph node region and extranodal site. For the detection of peripheral lymph 
nodes, the sensitivity of SS-R scintigraphy appears inferior to physical examination and 
CT scanning. CT scanning is also superior for the visualization of nodal lesions in the 
thorax and abdominal region. CT scanning and SS-R scintigraphy each have a low 
sensitivity for gastrointestinal and orbit/eye localizations. 
Discussion 
SS-R scintigraphy has been shown to be a useful imaging tool in a wide variety of SS-R 
bearing tumors, including neuroendocrine cancers. brain tumors, breast cancer, and 
Hodgkin's disease ( 4,21 ,22). Although previous in vitro studies indicated the presence of 
SS-Rs in lymph nodes with NHLs (5), only a few studies have used SS-R scintigraphy. 
These studies were all based on a small number of patients. varying from 4 to 28 patients 
with NHL (6-13). Therefore, the clinical value of SS-R scintigraphy in the staging of 
NHLs has not been properly established. 
We report on the results of a prospective study that investigated the role of SS-R 
scintigraphy in the initial work-up of 50 patients with untreated low-grade NHL. Findings 
in SS-R scans were positive in 84% of the patients. There were 9 patients with a MALT 
lymphoma in whom SS-R sensitivity was comparatively low. A high proportion (44%) of 
SS-R scan findings were negative in patients with a MALT NHL. In our study, 3 of5 
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patients with primary gastric MALT lymphomas had positive findings. Raderer et al. (23) 
reported negative SS-R findings in all 15 investigated patients with primary gastric 
MALT lymphomas. These investigators suggested that the expression ofm.R.c"lA for SS-R 
subtypes 3 and 4, but not for SS-R subtype 2, in the gastric samples of their patients 
might explain the negative scanning results. The low sensitivity of SS-R scintigraphy in 
MALT lymphomas is similar to that of other imaging modalities, such as CT and FDG 
PET (24-27). 
In 20% of the patients, the new lesions revealed by SS-R scintigraphy resulted in an 
upgrading of the clinical stage. As a result, these findings would have affected the 
treatment plan in I 0% of the patients. These patients were restaged from stage I to stage 
III or stage IV and therefore were no longer eligible for curative radiotherapy. This 
discordance between SS-R scintigraphy and other techniques was not confirmed by 
biopsy. Although histologic confirmation would have been desirable, this process was not 
feasible in practice. On the other hand, in a substantial proportion (38%) of patients, 
lesions disclosed by conventional staging procedures were missed by SS-R scintigraphy. 
We estimated the lesion-related sensitivity at 55%. The sensitivity varied from 62% for 
supradiaphragmatic lesions to 44% for lesions below the diaphragm. SPECT of the upper 
part of the abdomen was of little value. In one patient, only SPECT disclosed an NHL 
lesion that was not apparent on the planar images. CT was superior to SS-R scintigraphy 
for the detection of nodal lesions and also for most extranodal sites. However, SS-R 
scintigraphy was superior to CT for gastrointestinal lesions, although both imaging 
modalities have a low sensitivity. 
The patient- and lesion-related sensitivity of SS-R scintigraphy in this study is higher 
than that reported by other groups (8,10,12,13), who found lesion-related sensitivities 
varying from 29% to 35% in patients with low-grade NHL. The number and selection of 
patients may explain part of this difference in sensitivity. In other published studies, the 
number of patients investigated with low-grade NHL ranges from 3 to 12 (6-13). In the 
study reported here, 50 newly diagnosed patients were enrolled, and a relative high 
proportion of these patients had stage I or stage II disease. Furthermore, differences in 
imaging protocol and dosage of 111 In or pentetreotide may also play a role. The majority 
of the lesions showed a relative small accumulation of radioactivity (i.e., grade I in 31% 
of lesions). Therefore, it is our opinion that the counting time should be long enough (at 
least 15 min) and the applied doses of the radionuclide should be sufficiently high (at 
least 200 MBq) to enhance the visibility of these lesions with relatively low uptake. 
Interestingly, Lipp et al. (13) were able to improve their previous reported results by 
doubling the doses of octreotide and 11 1ln and using extended SPECT. 
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The reported low sensitivity for low-grade NHLs is quite different from that for 
Hodgkin's disease. We, as well as other groups, have found a distinctly higher sensitivity 
(94%) in patients with Hodgkin's disease (8_12,21,22,28). This result may be partly 
explained by the fact that approximately 80% of the lesions in Hodgkin's disease show a 
high uptake of radioactivity (grade 2 or grade 3) (29). We also found a higher sensitivity 
(71 %) in patients with intermediate- and high-grade NHL (Lugtenburg, data not shown). 
In patients with low-grade NHL, the intensity of the uptake of radioactivity in the lesions 
is probably too low for the radiotherapeutic use of high doses of 111In-pentetreotide. 
Six false-positive SS-R scintigraphy findings were obtained, and three of these are 
notable. In the first patient, inflammatory reactions caused by extreme dental caries 
resulted in aspecific uptake in the jaw. Clinically, this patient suffered from gingivitis and 
paradontitis. The second patient had autoimmune hemolytic anemia and splenomegaly for 
several years. A high uptake of radioactivity occurred in the spleen, which histologically 
was not infiltrated with NHL. The third patient had an enlarged thyroid caused by a 
multinodular goiter. Cytopathologic examination of the thyroid did not reveal NHL. 
False-positive uptake in thyroid diseases has been described previously (30). In the last 
three patients, radioactivity accumulated at sites of recent operation, a known pitfall (4). 
We agree with Gibril et al. (30), who state that by thoroughly understanding the 
circumstances that can result in false-positive localization and comparing the SS-R 
scintigraphy result with the clinical context, a correct diagnosis can be made in almost 
every case. We found a high specificity for SS-R scintigraphy (98%-100%). 
The role of gallium scintigraphy in the staging of patients with NHL is still a subject of 
controversy. Available data in the literature indicate a low sensitivity of gallium 
scintigraphy in low-grade NHL. Even in studies using high-dose gallium and modern 
equipment, low sensitivities are reported ranging from 56% to 79% per patient and 32% 
to 69% per lesion (31-33). Therefore, gallium scintigraphy currently has no standard 
place in disease staging of malignant lymphoma. Whole-body FDG PET has been shown 
to detect both nodal and extranodal sites of disease in patients with Hodgkin's disease and 
)JHL (34,35). Several studies have shown that FDG PET is at least comparable with other 
imaging modalities such as CT (36,37). Sensitivities of 86%-89% have been reported 
(38). However, limited data have been published concerning the value of PET in the 
initial staging oflow-grade NHL (38,39). 
A shortcoming of our study is that no gold standard was obtained. This is a major 
problem in tumor staging for tumors that are widespread and cannot be subject to 
complete histologic evaluation. Sensitivities and specificities are difficult to assess in 
these types of studies. We defined criteria for assessment of lesions as benign, malignant, 
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or indeterminate as a second-best alternative. The assessment was based on the results of 
pathologic examination supplemented by the clinical course. Despite these shortcomings, 
we believe that the data are sufficiently solid to assess the value of SS-R scintigraphy in 
the initial staging of low-grade NHL. 
Optimal staging oflow-grade NHL is important for identifying those patients who present 
with truly localized disease and may be cured by radiotherapy. Although SS-R 
scintigraphy findings are positive in 84% of patients with low-grade NHL, our data 
indicate that SS-R scintigraphy is insufficiently sensitive. In most patients, not all of tbe 
lesions can be detected. This lack of sensitivity makes SS-R scintigraphy not generally 
useful in the initial staging of patients with low-grade NHL. However, its use may be 
considered in selected patients with stage I or II disease to identifY more extended 
disease. This use, of course, must be weighed against the high costs and patient burden. 
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Abstract 
In patients with intermediate- and high-grade non-Hodgkin's lymphoma (NHL) the stage 
of disease is a major prognostic factor, which has important implications on therapeutic 
strategy. Somatostatin receptor scintigraphy has been demonstrated to be successful in the 
visualization of SS-R bearing tumors. In this prospective study SS-R scintigraphy was 
compared with conventional staging techniques for the initial staging of patients with 
intermediate- and high-grade NHL. Ninety-four, newly diagnosed and previously 
untreated patients with intermediate- and high-grade NHL undenvent SS-R scintigraphy 
in addition to the standard diagnostic work-up. Planar images were obtained 24 and 48 h 
after intravenous injection of 220 'MBq 111In-pentetreotide. SPECT images were 
performed in all patients. The SS-R scan was positive in 85 of 94 (90%) patients. In 19 
patients (20%) the SS-R scan revealed new lesions suggestive of NHL, which had not 
been demonstrated following conventional staging procedures. In these 19 patients, as a 
consequence of the different SS-R scintigraphy findings, the clinical stage was upgraded. 
Consequently, the treatment plan would have been altered in 17 patients (18%). In 17 
patients (18%) lesions apparent following conventional staging methods were not 
visualized by SS-R scintigraphy. The sensitivity of SS-R scintigraphy varied from 77% 
for supradiaphragmatic lesions to 57% for infradiaphragmatic lesions. The specificity of 
SS-R scintigraphy was high (98%-100%). Our data indicate that SS-R may be useful in 
patients with clinical stage I intermediate- and high-grade NHL. where it may distinguish 
a subset of patients with extended 1\HL. 
Introduction 
In patients with intermediate- and high-grade non-Hodgkin's lymphomas (NHLs) it is 
important to distinguish between stage I and stage II-IV disease, because the choice of 
treatment is influenced by the stage of disease. The majority of patients (80%-90%) with 
truly localized stage I disease enjoy durable relapse free survival following short-course 
combination chemotherapy with or without radiotherapy (1-3). The treatment of choice 
for patients with more advanced disease is combination chemotherapy with long term 
disease free survival of approximately 30% (4). It is therefore essential that the patient is 
accurately staged at the time of diagnosis. 
A wide variety of imaging studies have been utilized in the staging of NHL. These 
include chest X-ray, computed tomography (CT) scan, lymphangiogram, ultrasound scan 
and magnetic resonance imaging (MRI). Of the radionuclide imaging techniques, gallium 
scintigraphy can be usefuL especially in re-evaluating patients after therapy. This holds 
particularly for those with residual masses (5,6). In the last decades considerable 
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technologic 
tomography 
advances in diagnostic radiology have been made. Spiral computed 
is standard today. Despite these technical improvements 
assessment of intra-abdominal nodal or organ involvement still represents 
problem. 
however, 
a clinical 
Somatostatin receptors (SS-Rs) are expressed on the surface of neoplastic cells in a wide 
variety of human tumors (7). SS-R scintigraphy with the radioactive somatostatin analog 
11 1In-pentetreotide has been demonstrated to be useful in imaging of SS-R bearing 
tumors, such as neuroendocrine cancers, brain tumors and breast cancer (7). By use of in 
vitro autoradiography the presence of SS-Rs were demonstrated in lymph nodes 
infiltrated with NHL (8). Particularly lymphomas of high-grade malignancy expressed 
SS-Rs at a high density. Studies assessing the clinical value of SS-R scintigraphy in the 
staging of NHLs are scarce. They are based on relatively small numbers of patients and 
heterogeneous patient groups (9-17). Hence, the diagnostic value of SS-R scintigraphy in 
patients with aggressive NHL has not been settled. 
Here, we report the results of a prospective study in 94 newly diagnosed patients with 
intermediate- and high-grade NHL, in which the findings of SS-R scintigraphy were 
evaluated in relation with those of the conventional work-up. 
Patients and methods 
Patients 
Ninety-four consecutive, newly diagnosed and previously untreated patients with 
intermediate- and high-grade NHL were emolled in a prospective study. The diagnosis of 
NHL had been substantiated by histologic and immunohistologic methods. Pathological 
diagnosis was classified according to the Working Formulation (18). The stage of the 
disease according to the Ann Arbor classification (19) was established following physical 
examination, inspection of the Waldeyer's ring by an ear, nose, and throat specialist, 
chest radiography and CT scanning of chest, abdomen and pelvis and sometimes 
ultrasonography of the neck or abdomen. The diagnosis of bone marrow involvement was 
always verified after cytologic, immunologic, and histopathologic exanrination of marrow 
aspiration and biopsy. CT scanning was performed with contiguous 10 nun axial sections 
after oral and intravenous administration of contrast material. All patients had given 
informed consent to the study, which had been approved by the ethics committee of the 
University Hospital Rotterdam. 
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SS-R scintigraphy 
In addition to the standard diagnostic work-up (see above), SS-R scintigraphy was 
planned. All examinations were completed before initiation of therapy. Patients were 
injected intravenously with 220 MBq 111Indium-labeled pentetreotide (OctreoScan, 
Mallinckrodt Medical BV, Petten, The Netherlands). Planar total body scintigraphy was 
performed 24 h after injection with a large-field-of-view gamma camera (Counterbalance 
3700 and ROTA II; Siemens Gammasonics, Erlangen, Germany) equipped with a 
medium-energy collimator. Repeated scintigrams were obtained 48 h after injection, 
when accumulation of radioactivity in the abdomen was observed on the 24-h 
scintigrams. Laxatives were given to reduce the presence of intestinal radioactivity, 
caused by some hepatobiliary clearance of 111 In-pentetreotide. Head and neck images 
were obtained anteriorly and laterally from both sides. The remainder of the body was 
imaged with separate anterior and posterior images of the thorax, upper abdomen 
(including liver/spleen and kidneys), lower abdomen and extremities. The thorax was 
imaged with arms elevated. Preset counts were 300.000 for the head and neck and 
500.000 for the thorax and abdomen or a maximum of 15 minutes. In all patients SPECT 
images of the upper abdomen were made 24 h after injection using a triple-head camera 
(3000XP. Picker, Cleveland, OH). SPECT data were reconstructed by filtered 
back-projection. A detailed description of the scanning protocol is given in several 
reviews (20-22). In healthy individuals a physiologic accumulation of radioactivity may 
be seen at 24 h after injection of 111 In-pentetreotide in the pituitary gland, thyroid gland, 
liver, spleen, kidneys. intestines, urinary bladder, and, frequently the gallbladder. 
Accumulation of radioactivity at other sites is considered to be abnormal and indicates 
the presence of pathologic SS-R positive tissue. In organs with physiologic uptake" of 
111In-pentetreotide (e.g. liver and spleen), inhomogeneous or focal uptake patterns were 
considered to be indicative of lymphoma. Independent, blinded evaluation of SS-R scans 
was performed by two experienced nuclear medicine physicians at the same time. If 
initial interpretations were different (occurring in less than 5% of cases), a blind 
discussion was held until consensus was reached. The intensity of pathologic uptake of 
111In-pentetreotide in the lesions observed on the planar images was graded 
semiquantitively as follows: grade 0 = negative, no abnormal activity; grade 1 = 
equivocally positive, small amount of accumulation of radioactivity; grade. 2 = clear 
accumulation of radioactivity. intensity less than that of the liver; grade 3 = clear 
accumulation of radioactivity, intensity equal to or greater than that of the liver. The SS-R 
scan was considered positive in any given patient if at least one of the identified 
lymphoma lesions was positive on the scan (grade L 2 or 3). 
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Assessment of the true state of a lesion or a region 
CT scans and other radiologic tests were evaluated by experienced radiologists without 
knowledge of SS-R scintigraphy data. Lymph nodes of more than 15 mm in diameter 
were considered unequivocally abnormal on CT scanning or ultrasonography and were 
interpreted to represent NHL. Lymph nodes of less than l 0 mm were considered benign. 
Lymph nodes with a diameter between 10 mm and 15 mm were considered equivocal. CT 
and ultrasound criteria for involvement in normal-sized spleen or liver included 
unexplained infiltrates or focal abnormalities of decreased attenuation. The spleen was 
considered enlarged on the CT scan, ultrasonography or SS-R scan if the longitudinal 
diameter was greater than 130 mm (23,24). 
Findings of SS-R scintigraphy were compared with the sum of conventional staging 
procedures. The following lymph node regions were evaluated: occipital left/right, upper 
cervical left/right, medial cervical left/right, supraclavicular left/right, submandibular 
left/right, preauricular left/right, infraclavicular left/right, axillary left/right, brachial 
left/right, mediastinal, lung-hilar left/right, para-aortic (including celiac nodes and nodes 
from the hepatic and splenic hili), iliac left/right, inguinal left/right, femoral left/right, 
popliteal left/right, mesenteric and the Waldeyer's ring. In addition, all possible 
extranodal sites of involvement were also evaluated. This resulted in a total of 70 
possibly involved lymph node regions and extranodal sites. In case of discrepant findings 
bet\veen SS-R scintigraphy and conventional staging procedures. we attempted to 
determine the status of the lesion. Discrepant findings were verified if possible by biopsy 
or by using non-invasive methods. including ultrasonography, MRI, CT or bone 
scintigraphy. All patients were followed during and after therapy. For any documented 
lesion a final assessment was made of its true state as benign, malignant, or 
indeterminate. This assessment was based on the results of pathologic examination 
(histology or cytology if done), supplemented by the subsequent clinical course. A lesion 
was considered benign because of pathologic evidence or if the size was less than I 0 mm 
in long-axis measurements and the lesion did not grow in size. A lesion was considered 
malignant because of pathologic evidence or if the largest diameter was more than 15 
mm, or in retrospect on the basis of the clinical course (disappearance or change in size of 
a lesion of more than 10 mm after therapy). The status of the lesion was considered 
indeterminate if the nature of the lesion could not be assessed from the data. Regions 
without lesions on any test were considered to have a true state of absence of disease. The 
spleen was considered posirive for NHL if there was unequivocal palpable splenomegaly 
alone or equivocal palpable splenomegaly with radiologic confirmation of either 
enlargement or multiple focal defects that were neither cystic nor vascular. Liver 
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involvement was diagnosed if there were multiple focal defects, which were not cystic or 
vascular, noted with at least two imaging techniques. 
Assessment of sensitivity and specificity of a test 
The sensitivity and specificity of the different tests were calculated separately for each of 
the regions for which each test was performed. For the calculation of sensitivity, the 
lesions with a true state of malignancy were used, whereas for the calculation of 
specificity, the regions with no lesions or only lesions with a final assessment of benign 
were used. The sensitivity of a test for a lymph node region or extranodal site was defined 
as the number of lesions with a positive test result for that region divided by the total 
number of lesions with a final assessment of malignant in that region. The specificity of a 
test for a lymph node region or extranodal site was defined as the number of patients with 
a negative test result divided by the total number of patients tested with a true state of 
benign/absent in that region. 
Results 
Patients 
The clinical characteristics of the 94 patients with intermediate- and high-grade NHL 
enrolled on study are listed in Table I. Forty-five percent of patients presented with 
diffuse large cell lymphoma. Forty percent of the patients had localized stage I disease 
and 31% stage IV. The majority (89%) of NHLs were immunophenotypically classified 
as B-cell lineage. T-cell lymphomas were a minority (8%). Details of the anatomic 
distribution of the malignant lesions are given in Table 2. Lymph nodes in the neck were 
seen in 53% of patients. Forty-five patients (48%) presented with infradiaphragmatic 
disease. In the latter instances the para-aortic lymph nodes were most frequently involved 
(33o/o of patients). The most frequent sites of extranodal involvement were the bones, 
stomach, testis and lung. Bone marrow infiltration with NHL was apparent in 10 patients 
(II%). 
Comparison of SS-R scintigraph)'' with conventional staging procedures 
The SS-R scan was positive in 85 of 94 (90%) patients. An entirely negative scan was 
seen in 9 of94 (10%) patients. All patients with a T-celllymphoma were positive on SS-
R scintigraphy. There was no apparent relationship between the pathologic classification 
and the probability of a negative SS-R scan. 
In Table 3, an overview is given of a comparison between the results of SS-R 
scintigraphy and the conventional staging procedures (exclusive bone marrow 
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Table 1. Clinical characteristics of 94 patients with intermediate- and high-grade ~HL 
Age (years) 
Median 
Range 
Sex 
:'vfale 
Female 
Ann Arbor clinical stage* 
Stage I 
Stage II 
Stage III 
Stage IV 
Histologic subtype (Working Formulation) 
D: follicular, predominantly large cell 
E: diffuse, small cleaved cell 
F: diffuse. mixed small cleaved and large cell 
G: diffuse, large cell 
H: large celL immunoblastic 
1: lymphoblastic 
MALT 
Unclassifiable intermediate/high grade 
Immunophenotype 
B-cell 
T-cell 
Other 
*based on the results of the standard staging procedures. 
58 
1 S-81 
62 (66%) 
32 (34%) 
38 (40%) 
18 (19%) 
9 (10%) 
29(31%) 
1 (1 %) 
2 (2%) 
18 (19%) 
42 (45%) 
8 (9%) 
1 (1%) 
6 (6%) 
16(17%) 
84 (89%) 
7 (S%) 
3 (3%) 
examination) in the 94 patients. In !9 patients (20%) the SS-R scan revealed new lesions 
indicative of NHL that had not been demonstrated following conventional staging 
procedures. In 6 of the latter 19 patients additional biopsy (n = I) or the subsequent 
clinical course (n = 5) provided additional support for active NHL at the positive sites of 
SS-R scintigraphy. In 17 patients (18%) lesions demonstrated following conventional 
staging were not apparent on SS-R scintigraphy. Furthermore. in 17 patients (18%) the 
results of the comparison were mixed~ i.e. in the same patient new lesions were disclosed 
by SS-R scintigraphy, but other lesions were missed. The results of SS-R scintigraphy 
and conventional staging procedures were entirely concordant in 44% of the patients. 
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Table 2. Distribution of 270 malignant lesions in 94 patients with intermediate- and high-
gradeKHL* 
Localization malignant lesion 
:-leek lymph nodes 
Para-aortic lymph nodes 
Mediastinal lymph nodes 
Waldeyer's ring 
A'<illary lymph nodes 
Mesenteric lymph nodes 
Bones 
Inguinal lymph nodes 
Iliac lymph nodes 
Spleen 
Stomach 
Testis 
Lung 
Intestine 
Lung hilar lymph nodes 
Skin 
CKS 
Thyroid 
Kidney 
Sinus/nose 
Mamma 
Liver 
Adrenal gland 
% of patients 
53 
33 
25 
20 
15 
9 
9 
7 
7 
7 
7 
6 
5 
4 
3 
3 
3 
3 
2 
2 
2 
*diagnosed on basis of conventional staging procedures and SS-R scintigraphy. 
Table 3. Comparison of results of SS-R scintigraphy with those of conventional staging in 
94 patients with intermediate- and high-grade NHL 
Patients 
Result ::.Jumber % 
SS-R scan detects new lesions 19 20 
SS-R scan misses lesions 17 18 
SS-R scan detects new lesions and 17 18 
misses lesions in same patient 
Agreement between SS-R scan and 41 44 
conventional staging procedures 
Table 4 shows the overall clinical stage based on the outcome of the conventional staging 
procedures (excluding the bone marrow evaluation) in comparison with the clinical stage 
established by SS-R scintigraphy findings only. 
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Table 4. Clinical stage based on the SS-R scintigraphy findings compared with the clinical 
stage based on the results of the conventional work-up 
Stage based on conventional staging procedures* 
Stage based on 
SS-R scan 
only II III IV 
2I 31 It 6"' 
II s"~ I3 1 4 
III s"~" 2 7 5 
IV i 0 0 14 
Total 38 IS 9 29 
~indicate a change in clinical stage with potential consequences for the treatment choice 
*conventional staging methods exclusive bone marrow pathology. 
Total 
31 
23 
19 
21 
94 
As a result of the additional SS-R scintigraphy findings the clinical stage would have 
been upgraded in 19 patients (20%). Consequently, the treatment plan would have been 
altered in 17 patients (18%). There were 20 patients (21%), in whom SS-R scintigraphy 
did not show otherwise apparent localizations of NHL, so that the clinical stage would 
have been underestimated, when based on the results of SS -R scintigraphy only. 
Lesion- related sensitivity and specificity of SS-R scintigraphy 
In the 94 patients, a total of 270 malignant lesions were distinguished considering the 
results of physical examination in combination with SS-R scintigraphy, X-ray, CT 
scanning, ultrasound, histopathology and considering the outcome of subsequent follow 
up. Of these, 175 lesions were localized above the diaphragm, 83 lesions were below the 
diaphragm and 12 were elsewbere. A minority of the lesions was extranodal (n ~54). In 
Table 5 the sensitivities of SS-R scintigraphy are given for detecting ).JHL in each of the 
lymph node regions and extranodal sites. For supradiaphragmatic nodal lesions the 
sensitivity varied from 61%-100%. A consistently high sensitivity was obtained for 
lesions in the supraclavicular region and mediastinum, respectively 91% and 87% (Figure 
1). The smallest NHL lesion above the diaphragm that was correctly visualized by SS -R 
scintigraphy was located in the supraclavicular region and had a diameter of 0.5 em. The 
largest supradiaphragmatic lesion that was missed on SS-R scintigraphy had a diameter of 
4.0 ern and was located in the Waldeyer's ring. The scintigraphic sensitivity for the 
detection ofNHL involvement in the abdominal and inguinal region ranged from 33% to 
86% (Figure 2). Only 33% of gastrointestinal lymphomas were seen on SS-R 
scintigraphy. ln the para-aortic region small lymph nodes of 1.0 em diameter were 
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Figure 1 
In this 53 year old man who presented with 
bilateral enlarged lymph nodes in the neck a 
high-grade malignancy :\"HL was diagnosed. 
Anterior image of the thorax at 24 h. SS-R 
scintigraphy showed clear uptake in 
:mpraclavicular lymph nodes on both sides and 
in the mediastinum (arrows). 
Figure 2 
SS-R scintigraphy in a 79 year old man with a 
high-grade malignancy ;.;HL and abdominal 
lymphoma localizations. Posterior view of the 
upper abdomen at 24 h. Pathological uptake is 
seen in the right lung (arrow), para-aortic, iliac 
and mesenteric lymph nodes (arrows). Note the 
high uptake in the enlarged spleen (S). 
Physiologic uptake is seen in the liver (L) and 
kidneys (K). 
detected by SS-R scintigraphy. However. one mesenteric lymph node mass of 15.0 em 
diameter was missed by SS-R scintigraphy. In three patients localizations ofNHL in the 
stomach and para-aortic region were demonstrated by SPECT only, while it had not been 
visualized on the planar images. In the other patients SPECT had no added value. The 
SS-R scan revealed all breast (2/2). skin (3/3) and bone (7/7) lesions (Figure 3). However. 
lesions in the kidneys (n ~ 3) and adrenal glands (n ~ 2) were missed. In only one often 
patients (I 0%) with bone marrow infiltration, the SS -R scan revealed marrow positivity. 
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Figure 3 
SS-R scintigraphy in a 64 year old man with an 
intermediate-grade malignancy NHL of the 
right ma.'>:illa and midccrvical lymph nodes at 
the right side of the neck. Right lateral anterior 
view of the head and neck at 24 h after 
injection. Clear visualization of the tumor in 
the ma.'<iila (grade 3 uptake, arrow) and small 
amount of accumulation of radioactivity in the 
lymph nodes in the neck (grade I uptake, 
arrow). Physiologic uptake is seen in the 
thyroid (T). 
The sensitivity of SS-R scintigraphy for all lesions combined was 71%, varying from 
77% for supradiaphragmatic lesions to 57% for lesions below the diaphragm. For nodal 
lesions the sensitivity was 72% and for extranodal sites 65%. The specificity of SS -R 
scintigraphy was high (98%-100%). The intensity of uptake of 111 ln-pentetreotide in the 
malignant lesions was: negative in 30%, grade 1 in 15%~ grade 2 in 39% and grade 3 in 
16%. The maximum uptake of 111 In-pentetreotide in the malignant lesions per patient 
was: negative in 12%, grade 1 in 16%, grade 2 in 46% and grade 3 in 26%. 
The SS-R scan detected 70 lesions in 38 patients for which the true state could not be 
reliably derived from histology, cytology or follow up. None of these lesions were 
detected by the other tests, except for one lesion in the lung -hilus that was positive on 
both the SS-R scan and X-thorax, but was not picked up by the CT scan. These lesions 
were excluded from the calculations of sensitivity and specificity. 
In 8 lesions, a false-positive result was obtained. In three patients nonspecific 
accumulation of radioactivity was caused by recent surgery (two hematomas and one 
surgical scar). A cerebral infarction caused aspecific uptake in the brain in the fourth 
patient. The fifth and sixth patient suffered from pneumonia and showed high uptake of 
radioactivity in the lungs. The seventh patient had grade 2 uptake in the submandibular 
region. Following palpation a mass of 1.5 em was shown. Histopathologic examination 
showed a salivary gland infiltrated with adenoid cystic carcinoma. In the last patient a 
histologically proven neurinoma (2. 0 em) caused grade 3 uptake of radioactivity in the 
supraclavicular region. 
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Sensitivity· of several imaging techniques 
Table 5 gives the estimated sensitivities of each of the imaging techniques applied, 
expressed per distinct lymph node region and individual extranodal site. In comparison 
with CT scanning, SS-R scintigraphy is inferior for the detection of l\HL lesions in the 
thorax and abdomen. CT scanning and SS-R scintigraphy share a low sensitivity for the 
visualization of NHL in the stomach and intestine. In the supraclavicular region SS-R 
scintigraphy offers the highest sensitivity. 
Discussion 
Several years ago the successful in vivo visualization of lymphoma lesions by SS-R 
scintigraphy after intravenous injection of 111In-pentetreotide was reported (7-9,14). 
Shortly tbereafter in vitro studies indicated the presence of SS-Rs in lymph nodes with 
NHL (8). Surprisingly, at present only a few studies have assessed the clinical value of 
SS-R scintigraphy in NHL. 
Here we report a prospective study in 94 patients with newly diagnosed untreated 
intermediate- and high-grade NHL, in whom the SS-R scan was positive in 90% of cases. 
Both intermediate-grade and high-grade NHL were positive on SS-R scintigraphy. There 
was no apparent relationship betv.,reen the histologic subtype according to the Working 
Formulation and the likelihood of a positive SS-R scan. This bigh rate of positive scans is 
in agreement with the high incidence of SS-R expression in NHL biopsies (8.14). To our 
knowledge this is the first study in which the effectiveness of other imaging and staging 
modalities as X-ray, CT scanning, ultrasonography and physical examination was 
prospectively assessed and compared with that of SS-R scintigraphy. CT scanning was 
superior to SS-R scintigraphy for the detection of nodal lesions in the thora-...:: and 
abdomen. Only in the supraclavicular region SS-R scintigraphy obtained the highest 
diagnostic yield. 
Previously unsuspected localizations, not recognized with other staging techniques, were 
found in 20% of patients by SS-R scintigraphy. In these patients the clinical value of SS-
R scintigraphy was demonstrated by an upgrading of the clinical stage. As a consequence 
of the additional lesions that were detected by SS-R scintigraphy 17 of94 (18%) patients 
were upstaged from stage I to stage II, III or IV disease. This change in stage is of 
therapeutic and prognostic importance. Stage I disease is generally treated with a limited 
series of 3 to 4 courses of chemotherapy with or without involved field radiotherapy. In 
contrast to more advanced disease, for which more extended chemotherapy is given. The 
additional findings of NHL on SS-R scintigraphy could be confirmed by biopsy in one 
patient. Furthermore, in 25% of the additional lesions identified by SS-R scanning the 
125 
Table 5. Sensitivity of various diagnostic approaches for the detection of intermediate~and high~grade NHL lesions in different lymph 
node regions and cxtranodnl sites 
Number of Physical Chest CT scan Sonography SS-R scan 
Localization of malignant lesion malignant examination radiograph (%) (%) (%) 
lesions (%) (%) 
~ 
Cervical lymph nodes* 56 84 83 (36) 68 
Supraclavicular lymph nodes 32 66 70 (20) 91 
Axillary lymph nodes 18 72 89 72 
lviediastinallymph nodes 23 64 (22) 91 87 
T.ung-hilar lymph nodes 3 100 100 100 
Waldeycr's ring 18 89 I 00 (7) 61 
Lung 9 67 89 67 
Para~nortic lymph nodes 31 84 67 (12) 61 
Mesenteric lymph nodes 8 100 80 (5) 50 
Inguinal lymph nodes II 82 100 64 
Iliac lymph nodes 10 70 70 
Stomach/intestine 9 33 33 
'<> Spleen 7 43 100 100(5) 86 
"' ' --·· r * occipital, submandibular and ceryicallymph nodes; LAG, bipedallymphangiogmphy. Numbers in parentheses indicate frequency at which the test was 
" <>: perfonned and arc given only if different from number of malignant lesions. 
"' 0: <'I u ~
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clinical data were consistent with NHL involvement at those sites. If the clinical stage 
had been based on the SS-R scintigraphy findings only, the stage would have been 
underestimated in 21% of cases. Thus, because certain lesions were not visualized on SS-
R scanning, the best results are apparently obtained if SS-R scintigraphy is performed in 
addition to CT scanning. 
We estimated the overall lesion-related sensitivity of SS-R scintigraphy at 71%. The 
sensitivity varied from a satisfactory value of 77% for supradiaphragmatic lesions to an 
unsatisfactory estimate of 57% for lesions below the diaphragm. SPECT imaging can 
increase the diagnostic effectiveness compared with planar SS-R scanning. However, 
SPECT of the upper part of the abdomen was of limited value. In three patients SPECT 
disclosed NHL lesions that were not visualized on the planar images. 
The low sensitivity in the abdominal region is also seen in low-grade NHL and Hodgkin's 
disease (Table 6) (25-27). Various factors are considered to interfere with the 
visualization of SS-R positive tumors with 111In-pentetreotide. Lymphoma lesions that are 
situated in or close to organs that accumulate the radioligand by receptor binding or 
clearance are difficult to detect selectively. Notoriously difficult areas for NHL staging 
by SS-R scintigraphy are the para-aortic and mesenteric lymph node regions and 
Table 6. Patient- and lesion- related sensitivity of SS-R scintigraphy in malignant lymphoma 
Diagnosis Number Uptake score Patient Lesion sensitivity 
(ref) of 2 or 3 sensitivity % 
patients (%of lesions) % Total Above Below 
diaphragm diaphragm 
LG-NHL 50 24 84 55 62 44 
(27) 
IH-NHL 94 55 90 71 77 57 
HD (25,26) 126 79 roo 94 98 67 
LG-NHL, low-grade NHL: IH-NHL, intermediate- and high-grade :-JHL: HD. Hodgkin's disease. 
lymphoma infiltration in liver, spleen and kidneys. SS-R scintigraphy shares this lack of 
sensitivity in the abdominal region with other imaging modalities like ultrasonography, 
CT scanning and gallium scintigraphy. 
The sensitivity of SS-R scintigraphy in intermediate- and high-grade NHL in our study is 
better than that reported by certain other groups. In three studies a lesion-related 
sensitivity of approximately 44% was found (9,11,13). However, the conclusions of these 
studies are based on only 6-l 0 patients with high-grade NHL. Our results are similar to 
those obtained by Bong et aL who reported a sensitivity of 72% in 26 patients with 
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intermediate- and high-grade NHL (15). Not only patient number and selection, but most 
likely also differences in imaging protocol and dosage of 111 In-pentetreotide may explain 
part of the reported differences in sensitivity. 
SS-R scintigraphy is positive in Hodgkin's disease as well as in NHL of low- and 
intermediate- and high-grade malignancy (Table 6) (9-17,25-27). The best results are 
obtained in Hodgkin's disease, where positive scans are found in all patients and the 
majority of lesions are visualized (25,26). Although the SS-R scan is positive in most 
patients with low-grade NHL, only approximately half of the lesions indeed are revealed 
in vivo by SS-R scintigraphy (27). We determined the intensity of uptake of radioactivity 
in the malignant lesions of all our patients with malignant lymphoma (Table 6). 
Interestingly, the highest uptake is seen in patients with Hodgkin's disease and the lowest 
in patients with low-grade NHL (26,27). The sensitivity of SS-R scintigraphy appears to 
correlate with the intensity of uptake of the radio ligand in the lesions. Sarda et al also 
found a lower sensitivity and a low tracer uptake in low-grade NHLs, although in a much 
smaller patient group (10). 
SS-R scintigraphy is a sensitive technique to show in vivo the presence and abundance of 
SS-Rs. Recently, a new therapy was developed taking advantage of this information. 
Several patients with end-stage neuroendocrine tumors were treated with multiple high 
doses of 111 In-pentetreotide. The results were promising and there was a tendency towards 
better results in patients whose tumors showed a higher accumulation of the radio ligand 
(28). 
The limitation of the specificity of SS-R scintigraphy for NHL is caused by the fact that 
SS-Rs are expressed in various other malignant tissues, e.g., neuroendocrine tumors, 
breast trunors, brain trunors and Hodgkin's disease (7). Granulomatous and autoimmune 
diseases may also express SS-Rs (29,30). We obtained false-positive results in 8 patients. 
In five of these cases recent surgery and infections had caused the aspecific uptake of 
radioactivity. These obviously pitfalls must be born in mind for a correct interpretation of 
SS-R scintigrams (7,31). In two other cases a carcinoma of the salivary gland and a 
neurinoma gave a false-positive scan. 
Gallium scintigraphy using high-dose. modem equipment and SPECT may play an 
important role in the evaluation of the treatment response in patients with NHL 
(5,6,32,33). However, in the initial staging of patients with newly diagnosed NHL the 
role of gallium scintigraphy is still subject of controversy. Prospective studies using high-
dose gallium and modern equipment in untreated patients with intermediate- and high-
grade NHL are scarce. Sensitivities have ranged from 59%-89% (34-38). Whole body 
FDG-PET has been shown to detect both nodal and extranodal sites of disease in patients 
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with HD and NHL (39-42). Although preliminary results are encouraging, its role in the 
staging ofNHL has yet to be defined. 
Optimal staging of intermediate- and high-grade NHL is important for identifying those 
patients who present with truly localized stage I disease. As SS-R scintigraphy is positive 
in the majority of patients (90%) with intermediate- and high-grade NHL, SS-R 
scintigraphy may be applied together with CT scanning for more accurate staging in 
selected patients with NHL. SS-R scintigraphy may be particularly useful in individuals 
with clinical stage I NHL, where it may distinguish a subset of patients with extended 
lymphoma. 
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CHAPTER 7 
Summary and general discussion 

SUMMARY AND GENERAL DISCC:SS!O); 
At the time of initial presentation of malignant lymphoma the range of therapeutic 
options is broadest and the chance of cure greatest. The objectives of initial staging are 
not only to defme the local extent of clinically overt disease as exactly as possible, but 
also to disclose occult disease elsewhere. In designing an imaging strategy to search for 
occult sites of disease, one should be aware of preferential sites of tumor involvement, the 
sensitivity and specificity of the tests for particular sites and the likely impact on 
treatment. Computed tomography (CT) of thorax, abdomen and pelvis currently 
represents the standard imaging teclmique in patients with malignant lymphoma, even 
though it has shortcomings. Following therapy CT as well as magnetic resonance imaging 
(MRI) perform suboptimally in distinguishing fibrotic scar tissue from residual viable 
tumor. CT is also inadequate for demonstrating lymphoma involvement in spleen or liver. 
Therefore, an accurate non-invasive evaluation of the extent of disease currently remains 
a continuing challenge in the clinical management of patients with lymphoma. 
Fourteen years have elapsed since somatostatin receptor (SS-R) scintigraphy was 
introduced (I), Subsequent clinical studies have demonstrated the successful visualization 
of SS-R positive neuroendocrine tumors after intravenous administration of a 
radio labeled analog of SS and subsequent radionuclide scanning, In a small pilot study it 
became evident that it was possible to visualize non-Hodgkin's lymphoma (NHL) and 
Hodgkin's disease (HD) in vivo using SS-R scintigraphy with "'Indium-pentetreotide 
(2). At the same time the tissue expression of SS-Rs in biopsies of malignant lymph 
nodes of these patients was demonstrated with in vitro autoradiography (2). 
In the studies presented in this thesis we have evaluated SS-R scintigraphy in the staging 
of untreated patients with HD and NHL. 
7.1 Place ofSS-R scintigraphy in the staging of Hodgkin's disease 
Favorable results with SS-R scintigraphy were obtained in patients with HD (chapters 2 
and 4). All l26 patients with newly diagnosed HD were positive on SS-R scintigraphy, 
indicating the high frequency of SS-R expression in Hodgkin's lymphomas, Hence, SS-R 
scintigraphy can conveniently be used in patients with HD to investigate the spread of the 
disease. In the majority of patients with HD the neoplastic lesions show a high uptake of 
radioactivity and can readily be detected. In addition, 'new' lymphoma lesions frequently 
became apparent following additional SS-R scanning. SS-R scintigraphy showed 
excellent sensitivities for the detection of Hodgkin's localizations in the neck, axilla and 
mediastinum (95%-100%). Indeed, in comparison with CT scanning and ultrasonography, 
SS-R scintigraphy proved to be the most sensitive imaging technique for 
supradiaphragmatic Hodgkin's disease. In contrast, CT scanning offers the highest 
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sensitivity in the intra-abdominal region, where SS-R scintigraphy showed inferior 
sensitivities of 38%-100%. In a substantial proportion of stage I and stage II HD patients 
more extensive disease was demonstrated following work-up with SS-R scintigraphy. As 
a result of this patients were upstaged from stages Ill! to stages III or IV. This may have 
apparent implications for planning treatment strategies in these patients. 
Would the results ofSS-R scintigraphy have influenced patient outcome? It is not easy to 
provide a direct answer. It will be difficult to directly demonstrate in quantitative terms 
how changes in patient management based upon information from SS-R scintigraphy 
might contribute to eventual improvement in patient outcome. In the studies described in 
this thesis, it was agreed that new lesions that were found using SS-R scintigraphy would 
not influence patient management, unless the presence of active HD was proven. 
Therefore, possible benefits for the patient in terms of an improvement in prognosis can 
only be estimated in scenario estimates. A prospective randomised study could determine 
if a group in which treatment is changed because of the additional lesions found 
following SS-R scintigraphy will have a better outcome compared with a conventionally 
treated group in which the initial protocol is continued, independent of the SS-R 
scintigraphy results. Such a study would require large numbers of patients. Based on our 
own estimations, in a cost-effective analysis, the addition of a SS-R scan to the 
conventional staging procedures proved to be cost-effective in patients with stages I and 
II HD. In this analysis, it was demonstrated that the costs of the SS-R scan would be 
counterbalanced by a gain in life expectation (data not shown). 
7.2 Place ofSS-R scintigraphy in the staging ofnon-Hodgkin's lymphoma 
Histologic subtype and clinical parameters, rather than extent of disease provide the 
major prognostic factors in NHL. We conducted studies on SS-R scintigraphy in patients 
with indolent NHL (chapter 5) and more aggressive NHL (chapter 6), respectively. 
Although a majority (84%) of patients with indolent NHL have a positive scan, the 
overall sensitivity of SS-R scintigraphy was only 55%. A selective analysis of the results 
of SS-R scintigraphy in the subset of patients with a positive scan only, confirmed the 
low sensitivity of 60%. In fact, in many patients lesions are missed by SS-R scintigraphy. 
In a direct comparison with CT scanning, SS-R scintigraphy is inferior for the detection 
of nodal as well as most extranodallesions. Thus, the clinical value ofSS-R scintigraphy 
in staging of patients with indolent NHL is limited (chapter 5). 
The SS-R scan was positive in 90% of patients with an aggressive NHL (chapter 6). Both, 
B-ee!! and T -cell lymphomas were positive on SS-R scintigraphy. The overall sensitivity 
of SS-R scintigraphy was 71%. The best sensitivity was reached in the supradiaphrag-
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marie region (77%), the sensitivity was worst in the abdominal region (57%). SS-R 
scintigraphy was inferior to CT scanning for the detection of nodal lesions in the thorax 
and abdomen. However, in 20% of patients more advanced disease was demonstrated 
following SS-R scintigraphy. In 18% of patients the clinical stage was upstaged from 
stage I to stages II, III or IV. Thus. the results of SS-R scintigraphy could directly impact 
on therapeutic management in these individuals. In particular in patients with stage I 
disease, the addition of SS-R scintigraphy to the conventional staging approach may lead 
to the discovery of extensive disease. In this selected patient group the use of SS-R 
scintigraphy may therefore be considered. 
Primary cutaneous NHL is an infrequent distinct entity ofNHL, which arises in the skin. 
Although at presentation only the skin is involved, the disease subsequently may progress 
to involve lymph nodes and organs. The experience with SS-R scintigraphy in 14 patients 
with primary cutaneous NHL are reported in chapter 3. In contrast to CT scanning, SS-R 
scintigraphy appeared useful to differentiate between benign dermatopathic 
lymphadenopathy and malignant lymph node infiltration. Although the number of 
evaluated patients was small, this result warrants further study in a larger group of 
patients. 
7.3 Future issues in imaging Hodgkin's disease and non~ Hodgkin's lymphoma 
Several imaging techniques have been introduced for the visualization of malignant 
lymphoma e.g., CT, MRI, gallium scanning and FDG-PET scanning. What is the value of 
each of these diagnostic methods and how could their use contribute to optimise the 
diagnostic work-up in these patients? 
MRI has no standard place in the staging of malignant lymphoma. In general MRI 
provides little incremental information compared to CT scanning at the time of initial 
staging (3). MRI depends on the same lymph node size criteria as CT for an interpretation 
of lymphadenopathy. Moreover, CT is more practical as a 'whole body' staging 
procedure than MRI. However, MRI appears to be useful in specific situations. MRI may 
be more sensitive than blind biopsy in detecting bone marrow infiltration (4). In contrast 
to CT, involvement of the chest wall can be identified by MRI independent of anatomic 
distortion (5). MRI is the imaging method of choice for the detection of central nervous 
system involvement in malignant lymphoma ( 6, 7). There is no conclusive evidence that 
MRI can reliably predict relapse within a residual mass after treatment for lymphoma. 
The sensitivity is probably too low (about 45%) (8). MRI does not involve exposure to 
radiation, which is an advantage of this technique. A limitation of MRI is that it is 
contraindicated in patients with pacemakers. 
139 
CHAPTER 7 
The role of gallium imaging continues to be controversial in the staging evaluation of 
patients with malignant lymphoma. The reason why gallium scintigraphy has not been 
broadly established relates to the variable sensitivity of the procedure, depending on the 
anatomic location of the tumor, as well as the histology of the lymphoma. The overall 
sensitivity is highly dependent on lesion size. The minimal detectable lesion with 67 Ga 
scan is usually above 1 em in diameter. Most studies document a low sensitivity of about 
60% in the evaluation of abdominal disease (9,10). Detection of hepatic and splenic 
involvement is difficult because of the physiological uptake of 67 Ga by these organs. 
Several investigators have noted that gallium avidity varies with tumor histology, the 
aggressive NHL and HD are more often gallium positive than the indolent NHL 
(9,11,12). Because of the relatively low sensitivity, gallium scintigraphy uncommonly 
detects occult disease not documented by other non-invasive studies, and actual upstaging 
of disease as a result of findings on gallium scanning is rare. In addition to the initial 
work-up, patients with treated HD and NHL might also benefit from functional methods 
to differentiate a residual mass. Accurate monitoring of response to therapy is vital for 
subsequent treatment decisiOn. To diagnose relapse or resistant disease in patients with 
HD and aggressive NHL as early as possible, many consider gallium scanning as the 
standard in judging the residual mass (13,14). The positive predictive value of a post-
treatment gallium scan is high. However, the negative predictive value is much lower 
(14). Gallium imaging has inherent shortcomings. Besides the already mentioned lack of 
sensitivity in the abdomen and for lesions smaller than 2 em, post-therapy non-specific 
hilar uptake and uptake in the regenerating thymus constitute difficulties, especially in 
patients with mediastinal and hilar involvement (15,16). 
FDG-PET has been reported to be highly accurate in the staging ofHD and NHL prior to 
therapy. In most studies the diagnostic efficiency ofFDG-PET for nodal involvement was 
equivalent or superior to that ofCT (17-19). Three studies have reported the superiority 
of FDG-PET over CT in the detection of extranodal lesions (20-22). FDG-PET 
demonstrated greater tumor extension in the stomach than was found following 
endoscopy or on CT scans (21). Another study showed that FDG-PET is capable of 
demonstrating discrete. clinically occult skeletal involvement (20). Accurate 
identification of lymphoma infiltration in liver and spleen is an unresolved issue in 
staging. The sensitivity of CT, ultrasonography and gallium scanning has ranged between 
15% and 63% (17). Although the experience on this issue is limited, FDG-PET is able to 
detect liver and spleen lesions with high glycolytic activity (17,20,23). In one study FDG-
PET localized 66% more spleen lesions than CT (20). Evaluation of bone marrow with 
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FDG-PET may lead to many false-negative and false-positive results (I 7). Therefore, 
FDG-PET cannot replace bone marrow biopsy. 
Some investigators believe that FDG-PET would be most informative as a non-invasive 
modality in differentiating recurrence or residual disease from fibrosis. The reported data 
in literature are still limited and not unambiguous. Positive and negative predictive values 
between 57% and 100% have been reported (17). In some studies the high false-positive 
results have created doubts on the practical utility ofFDG-PET (8.17). Several organs in 
the body can show physiologically normal but relatively intense FDG activity that can 
pose problems in detection of tumors. The most notable regions for physiological FDG 
uptake are brain, heart, liver, bladder and bowel. False-positive results can be seen at the 
site of thymic hyperplasia (24). On the other hand, FDG-PET offers certain potential 
advantages over gallium scanning and SS-R scintigraphy. The interpretation ofFDG-PET 
in the abdominal region is less impeded by bowel excretion of radionuclides. Moreover, 
imaging is possible within one hour of FDG injection, unlike gallium and n 1Indium-
pentetreotide, which require long intervals between injection and imaging. 
There are no published data of studies investigating the role of SS-R scintigraphy for the 
evaluation of the treatment response in patients with malignant lymphoma. However, it is 
our experience that SS-R scintigraphy is capable of demonstrating relapse of malignant 
lymphoma in previously treated patients (data not shown). In Table I an overview is 
presented of the value of various imaging techniques that can be used for the imaging of 
malignant lymphoma. 
Further studies comparing FDG-PET to gallium scintigraphy and SS-R scintigraphy are 
warranted. These studies may also address the question of the best cost-benefit approach 
of patients with residual masses at the end of treatment. 
7.4 New developments in SS-R imaging 
SS-R expressing tumors can be viSualized by injecting a radiolabeled SS analog and 
imaging tissue uptake of the radionuclide via scintigraphy. Selective radioactive uptake 
will depend on the density and affinity of the receptor population. Scintigraphy with 
radio labeled ligands of octreotide will only allow the detection of tumors expressing SS-
R subtypes 2 and 5 and possibly those neoplasms expressing SS-R subtype 3. Recent 
reports suggest the existence of different SS-R subtypes on some human cancers, which 
bind the synthetic SS analogs differentially (25). Besides octreotide, several other SS 
analogs have been synthesized. These are currently used therapeutically in patients with 
acromegaly and neuroendocrine tumors (e.g., lanreotide and vapreotide ). 
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Table 1. Place of different imaging techniques in the management of malignant lymphoma 
CT scanning 
MRI 
Gallium 
scintigraphy 
SS-R 
scintigraphy 
FDG-PET 
scanning 
Initial staging Posttreatment Targeted Cost 
----------- evaluation therapy (relative) 
l\odal Extranodal 
sensitivity sensitivity 
High Low 
High Low 
Intermediate Low 
Intermediate Low-
-high intermediate 
High High? 
PPVlow 
NPVhigh 
PPVlow 
NPV low-intermediate 
PPV high 
1\'PV intermediate 
~o data 
PPV intermediate-high 
NPV intermediate-high 
Low 
Intermediate 
High 
High 
High 
PPV, positive predictive value; NPV. negative predictive value. 
The biological actions of these peptides are not always identical. These differences 
appear to be related to tbe different affinities of tbe natural hormone and synthetic 
derivates for the different SS-R subtypes. l\ew 'receptor-selective' and 'universal' 
radiolabeled SS analogs are being developed and migbt be of interest for future use in 
cancer patients as radiopharmaceuticals for imaging those SS-R positive tumors that 
express hSSTR-4, but not hSSTR-2 and hSSTR-5 and therefore do not bind octreotide. 
An example of such a 'universal' SS analog is DOTA-lanreotide. Compared with the 
parent peptide (i.e. lanreotide ). DOTA -lanreotide seems to display a distinct binding 
pattern, since it binds all transfected hSSTR subtypes as well as a variety of primary 
tumors. As a consequence, DOTA-lanreotide is claimed to be a 'universal' SS-R ligand 
(26). Chelated octreotides have also been labeled with positron -emitting 67 Ga, 64Cu or 18F. 
Of special interest is [64Cu-TETA-D-Phe1]-octreotide, which binds to SS-R at five-fold 
affinity as compared to 111 In-pentetreotide, and it has favorable clearance properties 
(renal clearance with rapid excretion) and is a potential agent applicable in PET imaging 
ofSS-Rs (27). 
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7.5 SS-R imaging as a guide in targeted treatment 
A new application of radio labeled peptides refers to their use in so-called peptide receptor 
radionuclide therapy. The underlying principle is to preferentially deliver radionuclides to 
the tumor using ligands that are capable of targeting the tumor. 111 Indium-pentetreotide 
has been used for radionuclide therapy in patients with advanced SS-R positive 
neuroendocrine tumors (28). In a clinical phase-! trial the capacity of 111 Indium-
pentetreotide was demonstrated to deliver radiation doses (20-75 GBq) to tumors that 
resulted in significant tumor shrinkage. The trial suggested greater responses in patients 
whose tumors had a higher accumulation of the radioligand. 111Indium-pentetreotide is 
not the ideal radiopharmaceutical for radionuclide therapy, because of the small particle 
range of the Auger electrons and, therefore, short tissue penetration. 
Recently, new alternative SS radio ligands have been synthesized, with the aim of using 
these for radionuclide therapy of tumors. One example is [DOTA-D-Phe1-Tyr']-
octreotide (DOTATOC or Octreother®). DOTA is a universal chelator, to which the high-
energy pure beta-particle emitter 90Y (Yttrium) and 177Lu (Lutetium), a low energy beta-
particle and gamma emitter can be linked in a stable manner. It can be expected that the 
radiotherapeutic use of radionuclides, such as 90Y, emitting the higher energies of beta-
particles, will permit for the delivery of higher radiation doses to greater parts of the 
tumor, also because of their more appropriate particle ranges or tissue penetration. Recent 
studies showed encouraging results after [90Y -DOTA -D-Phe1- Tyr']-octreotide treatment 
in patients with advanced cancer (29). Another example of such a new SS analog is 
octreotate. Reubi et al demonstrated a marked improvement of affinity for SS-R subtype 
2 for [Y-DOTA-Tyr']-octreotate and [In-DTPA-Tyr']-octreotate compared with [In-
DTPA-Phe3]-octreotide (30). Since most SS-R positive tumors, including malignant 
lymphomas, express the SS-R subtype 2, an improvement in affinity for the SS-R subtype 
2 may represent a considerable advantage as regards better tumor visualization and more 
effective therapy. Data from studies in tumor-bearing rats confirm the greater potential of 
radiolabeled octreotate over radiolabeled octreotide. The highest uptake in SS-R positive 
tumors and organs was seen following injection of the radiolabeled octreotate 
preparation. The latter radioligand also performed best for the visualization of these 
tumors (31,32). In a small comparative study in patients with SS-R positive tumors the 
uptake in the tumors was much higher after 177Lu-octreotate than that after 1l!In-
octreotide (33). Therefore, radiolabeled octreotate bas been selected for future (PET) 
imaging and targeted radiotherapy studies. The exquisite sensitivity of lymphoma to 
radiation together with the high frequency of SS-R expression in lymphomas may provide 
a rationale for the use of SS-R targeted radiotherapy in malignant lymphoma. As patients 
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with HD and aggressive NHL frequently show high uptake of the radio ligand, they would 
appear candidates for SS-R targeted radiotherapy. SS-R positive scintigrams could then 
be used to correlate images with treatment effects or predict whether SS-R targeted 
therapy would make sense. Also the effect of treatment can be evaluated conveniently by 
means of follow-up SS-R imaging. A variant approach of targeted treatment of SS-R 
expressing tumors is SS conjugated chemotherapy. By synthesizing conjugates of SS 
analogs (radioactive or non-radioactive) and cytostatic drugs selective accumulation of 
cytotoxic radicals in SS-R positive tumor cells may be exploited for therapeutic purposes. 
Future investigations should also be aimed at further exploring the use of long-acting SS 
analogs as antineoplastic agents, either alone or in combination with other drugs. Witzig 
et al reported that octreotide as single agent shows activity in patients with low-grade 
NHL (34). Recently, a high response rate was reported of a combination of 
cyclophosphamide together with SS, bromocriptin, retinoids, melatonin and ACTH in 
patients with low-grade NHL at advanced stage (35). The administration of SS is not 
associated with bone marrow toxicity. This may open the possibilities for the use of SS in 
combination with myelosuppressive chemotherapy regimens without enhancing 
myelosuppression. The combination of SS analogs with other classes of antineoplastic 
agents thus offers an interesting area for future studies. 
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Samenvatting 
Elk jaar word! in Nederland bij 2500 personen een maligne lymfoom gediagnostiseerd. 
In 80% van de gevallen betreft dit een non-Hodgkin lymfoom (NHL). De overige 
patienten hebben de ziekte van Hodgkin (Hodgkin lymfoom, HL ). De prognose van 
patienten met een maligne lymfoom is de laatste 30 jaar verbeterd. Dit is niet aileen te 
danken aan betere behandelingsmogelijkheden, maar ook aan gevoeligere diagnostische 
methoden om de verspreiding van de ziekte in bet lichaam op te sporen. 
Bij patienten met een maligne lymfoom is het voor de prognose en voor het vaststellen 
van de behandeling van essentieel belang om de uitbreiding van de zieh:te in het lichaam 
te detecteren. Bij iedere nieuw gediagnostiseerde patient met een maligne lymfoom wordt 
daarom een stageringsonderzoek verricht. Dit stageringsonderzoek bestaat meestal naast 
de anamnese en het lichamelijk onderzoek uit beenmergonderzoek en een aantal 
r6ntgenologische onderzoeken. Het standaard r6ntgenologisch onderzoek omvat over het 
algemeen een X-thorax, CT scan van thorax, abdomen en bekken, soms aangevuld met 
een echografisch onderzoek van de hals of bovenbuik De huidige methoden ter detectie 
van maligne lymfoomlokalisaties zijn niet optimaal. De sensitiviteit van de CT scan, MRI 
en echografie voor het aantonen van lymfoominfiltratie in lever en milt is laag. Ook 
aangedane lymfeklieren in de bovenbuik, lever- en milthilus en het mesenterium worden 
frequent gemist. Bij de CT scan en de MRI wordt de grootte van de lymfek:lier als 
criterium gehanteerd voor de beoordeling van lymfadenopathie. Er is echter gebleken dat 
een vergrote lymfeklier niet altijd maligne is en omgekeerd kan een niet vergrote 
lymfeklier maligne weefsel bevatten. Daarnaast kunnen de CT scan en de MRI in een 
restmassa, welke is achtergebleven na behandeling van de ziekte, geen goed onderscheid 
maken tussen fibrotisch Iitteken weefsel en nog actieve ziekte. 
Somatostatine receptor (SS-R) positieve neuroendocriene tumoren klll1Ilen succesvol 
scintigrafisch worden gevisualiseerd na toediening van het radioactief gekoppelde 
somatostarine (SS) analogon 111 In-pentetreotide. In een kleine pilotstndie bleek het 
mogelijk door middel van SS-R scintigrafie lymfoomlokalisaties zichtbaar te maken in 
patienten met een NHL en HL. Tevens werd door middel van in vitro autoradiografie met 
radioactief gemerk.'t SS aangetoond dat de lymfeklieren van deze patienten SS-Rn tot 
expressie brengen. In dit proefschrift worden een aantal prospectieve studies 
gepresenteerd. waarin de waarde wordt onderzocht van SS-R scintigrafie bij de primaire 
stagering van patienten met een NHL en HL. 
In de hoofdstukken 2 en 4 worden de resultaten beschreven van het onderzoek bij 
patienten met een HL. Alle 126 HL patienten hebben een positieve SS-R scan. Hieruit 
kunnen we concluderen dat SS-R scintigrafie zonder uitzondering kan worden toegepast 
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bij iedere nieuw gediagnostiseerde patient met een HL. In vergelijking met de CT scan en 
echografie blijkt SS-R scintigrafie de hoogste sensitiviteit te hebben voor het opsporen 
van Hodgkin lokalisaties boven het diafragrna. Voor Hodgkin lokalisaties onder het 
diafragma is de CT scan echter de meest gevoelige techniek. De prognose en de 
behandeling van een HL worden voor een belangrijk dee! bepaald door de uitbreiding van 
de ziekte. SS-R scintigrafie blijkt een duidelijke meerwaarde te hebben bij HL patienten 
met een stadium I of II. Bij een belangrijk dee! (20%) van deze patienten vindt SS-R 
scintigrafie nieuwe lesies, welke niet ontdek.'i zijn met het conventionele onderzoek. 
Hierdoor stijgt het stadium van de ziekte naar een stadium III of!V. Dit heeft belangrijke 
consequenties voor de prognose en de behandeling. Het is dan ook bij de groep patienten 
met een stadium I of II, dat de toepassing van SS-R scintigrafie wordt geadviseerd. 
De prognose en de behandeling van een NHL hangt meer samen met bet histologische 
subtype en bepaalde klinische parameters, dan met de uitbreiding van de ziekte. Studies 
met SS-R scintigrafie in patienten met een indolent NHL en in patienten met een meer 
aggressiefNHL worden in respectievelijk hoofdstuk 5 en hoofstuk 6 beschreven. 
Hoewel een groat dee! (84%) van de patienten met een indolent NHL een positieve scan 
heeft, bedraagt de sensitiviteit van SS~R scintigrafie slechts 55%. Bij veel patienten 
worden door SS-R scintigrafie lokalisaties van de ziekte gemist. Dit betreft lokalisaties 
zowel boven als onder het diafragma. De klinische waarde van SS-R scintigrafie bij de 
stagering van patienten met een indolent NHL is dan ook beperkt (hoofdstuk 5). 
De SS-R scan is positief bij 90% van de patienten met een meer aggressief NHL 
(hoofdstuk 6). De hoogste sensitiviteit (77%) wordt bereib:t voor lokalisaties boven het 
diafragrna. De sensitiviteit is het laagst in het abdominale gebied (57%). Voor het 
opsporen van nodale lokalisaties in de thorax en buikholte is de CT scan beter dan SS-R 
scintigrafie. Echter bij 20% van de patienten wordt door SS-R scintigrafie een meer 
uitgebreide ziekte gevonden. Bij 18% van de patienten leidt dit tot een ophoging van het 
klinische stadium van een stadium I naar een stadium II, III of IV, hetgeen gevolgen heeft 
voor de prognose en de behandeling van deze patienten. Bij patienten met een stadium I 
aggressief NHL kan de toevoeging van SS-R scintigrafie aan het conventionele 
onderzoek leiden tot de ontdekking van een meer gedissemineerde ziekte. In deze 
specifieke patientengroep kan daarom de toepassing van SS-R scintigrafie worden 
overwogen. 
Primair cutane NHLn vormen een zeldzame entiteit binnen de NHLn. Aanvankelijk 
bevindt de ziekte zich in de huid, later kan verspreiding optreden naar de lymfeklieren en 
organen. In hoofstuk 3 worden ervaringen beschreven met SS-R scintigrafie in 14 
patienten met een primair cutaan NHL. In tegenstelling tot met de CT scan, blijl-.1: het met 
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SS-R scintigrafie mogelijk om te differentieren tussen benigne dermatopatische 
lymfadenopathie en maligne lymfoominfiltratie van de lymfeklier. 
In hoofdstuk 7 volgt een discussie van de resultaten van de onderzoeken, die beschreven 
zijn in dit proefschrift. Er word! besproken welke plaats SS-R scintigrafie zou kunnen 
innemen in de stagering van maligne lymfomen. Van verscheidene andere 
beeldvormende technieken die gebruikt worden voor de visualisatie van maligne 
lymfomen. zoals de CT scan, MRl, gallium scintigrafie en de FDG-PET scan. worden de 
sterke en zwakke punten belicht. Vervolgens worden een aantal nieuwe ontwikkelingen 
genoemd waarmee de scintigrafische visualisatie van SS-R-positieve tumoren zou kunnen 
verbeteren. Tenslotte wordt een nieuwe klinische toepassing besproken van SS, namelijk 
het therapeutisch gebruik van radioactieve verbindingen van SS analoga. 
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jaren de samenwerking op het gebied van de beeldvorming en behandeling van lymfomen 
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Prof.dr. S.W.J. Lamberts, beste Steven, ik wilje danken voor je steun en belangstelling in 
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pronunciation. 
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onder Ieiding van Prof.dr. J.D.F. Habbema, dank ik voor de prettige samenwerking. Aan 
de vele sessies met Rene Eijkemans en het uitzicht vanuit zijn kamer bewaar ik goede 
herinneringen. Ze waren allemaal van hoog niveau. 
Mijn beide research verpleegkundigen Janneke Sluys-Dallinga en Petra BJorn dank ik 
voor hun geweldige inzet voor dit onderzoek. De duizenden gegevens van patienten die 
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door jullie werden achterhaald en nauwkeurig ingevoerd in de D-base vormen de 
bouwstenen van dit proefschrift. Dit boekje was er zonder jullie hulp nooit gekomen. 
Mijn collega hematologen aan beide zijden van de tunnel dank ik voor de prettige 
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raken we ook daarbuiten steeds beter op elkaar ingespeeld. 
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